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SUMMARY
UPPER GASTROINTESTINAL BLEEDING AND FIBRINOLYSIS
About 30,000 people are admitted to hospital in the 
United Kingdom each year with upper gastrointestinal 
tract (GIT) bleeding and about 3,000 of those will die. 
Rebleeding after admission to hospital is one of the 
major factors contributing to this mortality. One factor 
which may cause rebleeding is lysis of the fibrin 
haemostatic plug which seals a leaking vessel. Previous 
studies have shown that fibrinolytic activity in the 
stomach and duodenum was increased in patients with 
peptic ulcer, was localised around the ulcer, and could 
be released by trauma to the stomach. The serum 
concentration of fibrin degradation products (FDP) was 
also increased in patients with recent GIT bleeding.
The main aim of this thesis was to measure systemic 
fibrinolytic activity in a series of patients with acute 
upper GIT bleeding, and to relate this to clinical 
outcome, in order to assess its possible role in 
pathogenesis of bleeding. In this prospective study, 122 
patients were studied on the morning after admission to 
hospital. All had routine endoscopy to establish the 
likely site of bleeding and the pathological cause of 
bleeding. Patients were divided into three groups: (1)
no transfusion or surgery required; (2) transfusion 
required; (3) those who required surgery and/or who
-  25 -
died.
Blood was taken from an arm vein for measurement of 
serum FDP, as well as the fibrinolytic activity of the 
euglobulin fraction of plasma (fibrin plate lysis area 
FPLA). The latter test is a global measurement of 
plasminogen activators and their inhibitors in the 
euglobulin fraction. Neither test was significantly 
related to site of bleeding, or to the pathology of the 
lesion. The FPLA test showed no correlation with 
outcome. However serum FDP was significantly higher in 
patients who required transfusion (Group 2) than in 
patients who did not (Group 1), and patients who died or 
required surgery (Group 3) had significantly higher 
levels compared to Group 2 (p <0.001). Thus the serum 
FDP level was shown, for the first time, to be of 
prognostic significance in acute upper GIT bleeding. 
Multivariate analysis confirmed independent prognostic 
value. A rapid screening test for raised serum FDP 
(latex agglutination test) was then evaluated in 36 
samples from the study. Of the 7 patients with a positive 
test, 5 required surgery or died. Hence this test may be 
clinically useful in assessment of severe or recurrent 
bleeding.
Further investigations were performed to clarify the 
relationship of serum FDP to outcome of acute GIT 
bleeding. To evaluate the possibility that blood 
transfusion may itself raise serum FDP, these were 
measured before and after blood transfusion in 10
-  26 -
patients: no significant change in levels was observed.
Because the serum FDP assay does not distinguish 
degradation products of fibrinogen from those of 
cross-linked fibrin, an assay for plasma levels of 
cross-linked fibrin degradation products (ELISA assay 
using monoclonal antibodies) was performed in 65 samples 
from the study. Mean levels were similar in Groups 1 and 
2, but significantly elevated in Group 3 (p <0.05). This 
confirms the association of poor outcome with lysis of 
cross-linked fibrin, e.g. in haemostatic plugs.
It was concluded that the association of lysis of 
fibrin with poor outcome after GIT bleeding is consistent 
with the hypothesis that fibrinolysis may play a role in 
promoting continued or recurrent bleeding. Further 
evidence for this comes from encouraging results of 
clinical trials of fibrinolytic inhibitor drugs, e.g. 
tranexamic acid.
The second aim of this thesis was to measure systemic 
fibrinolytic activity in patients with portal 
hypertension due to liver cirrhosis. In 10 patients with 
acute bleeding varices elevated serum FDP were again seen 
in patients who died or required surgery. In 54 patients 
without acute bleeding varices who attended for elective 
sclerotherapy, elevated levels of both serum FDP and FPLA 
were observed, being most marked in Child's Grade C 
patients, although this was not statistically significant 
for FPLA. The results of this study suggest that 
increased fibrinolysis, related to the severity of
-  27 -
cirrhosis, may play a role in bleeding from 
varices, and suggests evaluation of
inhibitor drugs in such patients.
oesophageal
fibrinolytic
- 28 -
CHAPTER I 
INTRODUCTION
Upper gastrointestinal bleeding continues to be a 
common and serious clinical problem in the author's 
clinical practice. In attempting to develop some insight 
into this condition, the literature has been reviewed 
with the following intentions:
(a) to establish some estimate of the frequency and 
seriousness of upper gastrointestinal bleeding 
(UGIT) bleeding in western populations
(b) to determine the factors which have been identified 
as influencing mortality in these patients
(c) to examine methods of treating this condition and 
suggest new possibilities for rational management.
1•1 Epidemiology of upper gastrointestinal bleeding
About 30,000 people each year are admitted to 
hospital in the United Kingdom with upper 
gastrointestinal bleeding and about 3,000 of these will 
die (Langman 1985). There is little evidence in the 
literature to suggest that this condition is becoming 
less of a problem.
(a) Incidence
Figures released by the health service in Scotland on 
discharges from hospital are not broken down in 
sufficient detail to permit assessment of the numbers 
presenting with UGIT bleeding. However, the Information 
and Statistics Division of the Common Services Agency of
29 -
the Scottish health service does publish details of the 
number of hospital discharges resulting from "peptic 
ulcer". These figures show a reduction in the number of 
admissions from 7,212 to 5,165 males and females between 
1979 and 1989. This might be expected in view of the 
increased use of H r e c e p t o r  antagonists over that 
decade. There is evidence, however, that this decrease in 
peptic ulcer admissions has not been accompanied by a 
decrease in episodes of bleeding. A study of admission 
rates for peptic ulcer and its complications carried out 
in Trent Regional Health Authority showed little change 
in the number of admissions to hospital for treatment of 
duodenal ulcer between 1972 and 1984 (Bardhan et al 
1989). A study of the pattern of admission showed a 
marked fall in the waiting list for elective treatment - 
73% in the period 1979-1984 - and a 40% increase in the 
number of emergency admissions. Included in this figure 
was an 8% rise in the number of admissions for 
haemorrhage.
The rise in the incidence of emergency presentation 
and decline in elective admission is not mirrored by the 
reported experience of other western centres. An early 
study of the effect of cimetidine on the incidence of 
bleeding, published only in abstract, suggested that the 
incidence of haemorrhage was decreasing despite an 
unchanged incidence of perforation (Thompson 1981). In 
European studies, admission rates for haemorrhage are
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reportedly increased in Finland (Tilvis et al 1987) and 
decreased in Greece (Archimandritis et al 1986). The 
American experience has been conflicting also. Kurata 
and colleagues reported a reduction in admissions with 
haemorrhage (1982) while the Mayo Clinic group reports no 
change in incidence (Gustavsson et al 1988).
(b) Age
It is clear that the average age of patients 
presenting with UGIT is increasing. Logan and Finlayson 
(1976) reviewed the literature and pointed out that less 
than 10% of patients admitted with UGIT bleeding before 
1930 were over 60 years of age whereas in the early 
1970's, 50% of patients were over this age. The Trent RHA 
study (Bardhan et al 1989) found that the number of 
patients with peptic ulcer over 65 admitted as an 
emergency increased by 36% while the admission rate with 
haemorrhage in the over 65's increased by 28%. The 
biggest increase in this study was found in women over 
the age of 65 and it must be a possibility that this 
increase may be related to the more widespread use of non 
steroidal anti-inflammatory drugs in elderly women with 
arthritis.
Changing population demography might be expected, 
therefore, to result in an increasing number of elderly, 
high risk patients being admitted to hospital with UGIT 
bleeding. A reducing incidence of peptic ulcer in the 
community due to improved understanding of the
31 -
pathogenesis of this disease and hence improved treatment 
may eventually work to decrease the number of deaths due 
to this cause but that effect is not yet apparent.
(c) Mortality
Undoubtedly, great advances have been made in the 
technology available to investigate and treat UGIT 
bleeding over the past 25 years. It is commonly held, 
however, that these advances have not resulted in any 
great improvement in mortality. Alan and Dykes (1976) 
summarized the mortality rate of UGIT bleeding in the 
period prior to 1940. They found that mortality ranged 
from l%-22% with a mean of around 10%. Piper and Stiel 
(1986) summarized the mortality from UGIT bleeding after 
1940 and drew a distinction between those treated before 
endoscopy came into routine use (1940-1973) and the 
period after 1975. A proper metanalysis was not done 
but a rough assessment of the figures showed that in the 
pre-endoscopy era, mortality ranged between 3 and 20%. 
After endoscopy came into widespread use, reported 
mortality ranged between 0 and 55%. The approximate mean 
mortality was about 10% in each case. Clearly, only the 
broadest of conclusions can be drawn from this paper 
since heterogeneous subgroups of patients were compared 
and many different treatment approaches were in use.
Overall, deaths from peptic ulceration numbered 4,259 
in England and Wales in 1983 (Taylor et al 1985). This 
paper confirmed the importance of UGIT haemorrhage as a
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threat to the elderly. Ninety five per cent of deaths 
were in patients over the age of 55 and the mean age of 
death for men was 69 and for women 74 (Office of 
Population Censuses and Surveys 1984, Bonnevie, 1978).
Furthermore, Pulvertaft showed in 1968 that both men 
and women over the age of 55 with a duodenal ulcer have a 
25% risk of major haemorrhage during the next decade of 
life. When they do bleed, they are at greater risk of 
dying. Kang and Piper (1980) studied 12 published series 
and confirmed a marked increase in mortality for those 
over 60 years of age.
While technological advance was not immediately 
translated into an improved survival, it became clear 
that endoscopy would have one major impact on the 
management of the condition: it allowed a distinction to
be made between patients according to the lesion which 
was seen to be bleeding. This was a significant advance. 
An immediate benefit was the ability to differentiate 
between bleeding due to peptic ulceration and oesophageal 
varices. Where varices were present on barium meal and 
rigid oesophagoscopy confirmed that they were bleeding, 
mortality was high. A series of studies from Higgin 
(1947), Atik and Simcone (1954), Nachla and colleagues 
(1955), Cohn and Blaisdell (1958), Taylor and Jonz 
(1959), Merrigan and colleagues (1960) and Orloff (1962) 
showed that mortality in these patients ranged from 34% 
to 80%. Hunt and colleagues (1983) showed, however, that
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the use of early, flexible endoscopy in these patients 
allowed an aggressive treatment regimen to be implemented 
and they reported improved mortality in varices patients 
from 35% to 17% in the periods 1972-1977 and 1977-1982 
respectively. During the same two time periods, mortality 
from bleeding duodenal ulcer improved from 13% to 6% and, 
in bleeding gastric ulcer, mortality also improved from 
34% to 3%. It was apparent from this study that an 
aggressive management policy could affect outcome of 
these patients. In addition to this encouraging 
observation, the information on the presentation and 
pattern of bleeding that was being obtained from direct 
observation down the endoscope was providing important 
insights into the pathogenesis of the disease. A number 
of factors influencing mortality could be defined.
1.2 Patient-related factors influencing mortality
Several authors have attempted to relate clinical and 
investigational findings to outcome and it is these which 
will form the main part of the review in this section.
(a) Clinical findings
There is disagreement as to whether the mode of 
presentation of gastrointestinal haemorrhage has 
prognostic significance. Northfield (1971) found that 
presentation with haematemesis alone was associated with 
a greater chance of further bleeding than presentation 
with melaena with or without haematemesis. Johnston et 
al (1974) found no such difference while MacLeod and
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Mills (1982) found that patients presenting with 
haematemesis had a significantly lower incidence of 
further haemorrhage than those presenting with melaena 
alone or with haematemesis.
Several workers have found that a history of recent 
alcohol ingestion prior to admission is associated with a 
more favourable outcome (Morgan et al 1977; MacLeod and 
Mills 1982). This may be due to the high incidence of 
erosive gastritis in this group of patients (MacLeod and 
Mills 1982) and may not apply to patients admitted with 
peptic ulceration. Blood group 0 patients with
gastric ulcer or duodenal ulcer are more likely to bleed 
and at an earlier age than other groups (Berg 1969).
Other clinical factors of importance are the presence 
of shock on admission. Balint (1977) pointed out the 
prognostic significance of an admission systolic blood 
pressure <100 mm Hg. This fact had been appreciated 
since Avery Jones' classic studies in the 1950's. 
Northfield and Smith (1970) at an early stage in the 
study of this problem stressed the importance of central 
venous pressure measurement in identifying those patients 
who were continuing to bleed. Low haemoglobin level on 
admission, as a sign of prolonged bleeding, has been 
found also to correlate with a poor outcome (MacLeod et 
al 1982, Himal et al 1974).
Further ominous clinical features were the 
association between UGIT bleeding and burns (Curling's
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ulcer) and head injuries (Cushing's ulcer) and sepsis. 
This appears to be an area where prophylactic use of 
antacids and H 2 receptor antagonists have had a positive 
effect in reducing the incidence of bleeding.
(b) Age
The increased risk of death with increasing age has 
already been alluded to. Recurrent bleeding is also a 
problem with elderly patients.
Mortality significantly increases in patients over 60 
years of age. MacLeod and Mills (1982) in Glasgow found 
that in all cases of upper gastrointestinal haemorrhage 
regardless of cause, 18% of patients under 60 years of 
age had further haemorrhage compared to 34% of the 
patients over that age although this has not been 
confirmed by others (Northfield 1971; Allan and Dykes 
1976; Morgan et al 1977). Similarly, in the Glasgow 
study (Macleod and Mills 1982), further haemorrhage from 
duodenal ulcers was more common in those patients over 60 
years of age but no significant difference was apparent 
for gastric ulcer.
(c) Site of bleeding
It is impossible to discuss mortality rate in this 
condition without relating outcome to the major changes 
that have taken place in the investigational technology 
available for UGIT disorders. Some mention of endoscopy 
has already been made in the context of mortality. It 
was pointed out that endoscopy has allowed
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differentiation between the major sources of bleeding to 
take place and has underlined the great differences in 
outcome between peptic ulcer and variceal bleeding.
In general, patients with bleeding duodenal ulcers 
have a mortality around 4% while patients with bleeding 
oesophageal varices have a mortality approximating 50%. 
If the site of bleeding is known prior to surgical or 
conservative therapy, mortality is about 5%. If the
source of haemorrhage is unknown prior to therapy, 
mortality is approximately 25% (Capper et al 1964; Himal 
et al 1974).
This is probably explained by the observation that 
having a potential bleeding source like peptic ulcer or 
oesophageal varices does not guarantee that it is the 
source of bleeding. Forrest and Finlayson (1974) found 
60% of patients having peptic ulcers were bleeding from 
that lesion, 21% of patients with no dyspeptic symptoms 
were bleeding from a peptic ulcer, 10-20% of patients 
with a history of peptic ulceration were bleeding from 
other lesions and 30-50% of portal hypertension patients 
were bleeding from lesions other than oesophageal 
varices.
Discussion of the investigation of haematemesis and 
melaena, particularly by endoscopy, becomes clouded by 
the increasing importance of endoscopy as a prognostic 
and therapeutic tool and further consideration of the 
information which can be gained from endoscopy and its
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application might best be considered in the next section. 
Before leaving this part of the discussion, however, it 
might be useful to summarise.
The number of admissions to western hospitals for 
treatment of peptic ulcer is decreasing but it appears 
that the number of admissions for treatment of the 
complications of this condition is not. In particular, 
UGIT haemorrhage incidence is probably static. More 
elderly patients are presenting with this condition and 
it is known that they have a higher mortality. Some 
attempt can be made to identify high risk patients on 
admission from clinical features such as blood pressure 
and haemoglobin. The presence of risk factors should 
alert the clinician to the need for action. Possible 
courses of action are now discussed.
1.3 Management options
The first major decision to be made after the initial 
steps have been taken to resuscitate the patient concerns 
early endoscopy. Much debate surrounds the question of 
timing of endoscopy,
a) Endoscopy: early or not
Protagonists of early endoscopy suggest that the 
procedure helps in the management of patients with 
gastrointestinal bleeding. Not only does it identify 
the site or sites of bleeding but it provides information 
about continuation of bleeding or signs of recent 
haemorrhage (Palmer 1969; Katon and Smith 1973; Foster et
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al 1978). An alternative view is that because most 
patients stop bleeding, irrespective of the cause 
(Schiller et al 1970), endoscopy should be reserved for 
patients who continue to bleed or who have recurrent 
bleeding (Winans 1977, Eastwood 1977). Most patients do 
stop bleeding with conservative measures and the
estimated incidence of continued bleeding ranges from 6% 
to 10% depending on the series. The rebleeding rate can 
however be as high as 25% and the mortality is greatest 
in patients who either continue to bleed or rebleed in 
hospital (Jones 1956). Thus in at least 70% of patients,
early endoscopy will not influence the management of the
patients as bleeding will stop. This observation may 
explain the apparent failure of endoscopy to improve 
mortality. Most studies are too small and therefore are 
subject to type II error. It is in patients in whom
bleeding continues or recurs that early diagnosis and 
vigorous therapy will be of greatest value. Therefore the 
timing of endoscopy in the management of acute 
gastrointestinal haemorrhage has been the subject of 
discussion (Conn 1981; Eastwood 1981). Controlled studies 
have failed to demonstrate an improvement in mortality 
rates in patients submitted to early endoscopy. Until 
recently the endoscopist was no better than the clinician 
at predicting whether bleeding would continue or recur.
Obviously, determination of recurrent or continuing 
bleeding is difficult unless it results in haemodynamic
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upset. A logical strategy would be to attempt to 
visualise the bleeding vessel directly and see if it is 
bleeding or if the likelihood of recurrent bleeding can 
be predicted.
b) Stigmata of recent haemorrhage
Signs of recent haemorrhage at endoscopy may indeed 
correlate with the likelihood of recurrent bleeding. 
Foster et al (1978) accepted that a lesion had bled only 
when one or more of the following stigmata were seen at 
endoscopy: fresh bleeding from the lesion; fresh or
altered blood clot or black slough adherent to the 
lesion; or vessel protruding from the base or margin of 
an ulcer. These stigmata were found in 69% of patients 
endoscoped within 12 hours of presentation and in about 
40% of patients endoscoped thereafter. Of their 233 
patients, 89 had peptic ulcers and stigmata of recent 
haemorrhage (SRH) were seen in 56% of patients with 
duodenal ulcers and 80% of those with gastric ulcers. In 
gastric ulcers with signs of recent haemorrhage the risk 
of recurrent bleeding was 30% compared to 0% when signs 
of recent haemorrhage were absent. In duodenal ulcer 
patients with signs of recent haemorrhage the risk of 
recurrent bleeding was 63% compared to 5%. Although only 
one patient without stigmata rebled, stigmata were 
associated with further haemorrhage in 42% of patients. 
In this retrospective study the use of clinical factors 
such as age, history of drug and alcohol ingestion,
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concomitant disease and shock proved much less reliable 
than the endoscopic findings at predicting outcome.
Griffiths et al (1979) found 'visible vessels' in the 
ulcer crater in 28 of 157 consecutive ulcer patients 
presenting with gastrointestinal haemorrhage. All 28 
patients subsequently required surgery because of 
uncontrolled bleeding while 79% of the patients without 
visible vessels in the base of an ulcer settled on 
conservative treatment. Surgical mortality was only 9% in 
patients with visible vessels compared to 35% in those 
patients without visible vessels. The mortality of those 
patients with visible vessels managed conservatively was 
83%. The authors conclude that surgery should be 
considered when a vessel is identified in the ulcer 
crater at endoscopy.
An excellent prospective study by Storey et al (1981) 
examined 292 patients admitted consecutively with acute 
gastrointestinal haemorrhage. All patients were
endoscoped within 24 hours of admission. They defined a 
visible vessel as an elevated red or blue spot that 
protruded from the ulcer crater and was resistant to
washing and often associated with a red clot. Otherwise, 
SRH were defined as oozing a fresh or altered blood clot 
adhering to the ulcer or black spots were seen in an
ulcer crater. An independent clinician observed the
patient in hospital over the next 7 days for evidence of
fresh bleeding. Of the 292 patients, 132 had peptic
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ulcer. In 117 patients in whom endoscopic examination was 
possible, 56 had a visible vessel and 21 other SRH. No 
such stigmata were present in 40. None of the latter 
had further bleeding, surgery or died. 56% patients with 
a visible vessel, had further bleeding, 50% of this group 
required surgery and operative mortality was 15% (5/34).
Of 13 patients with other SRH, 1 had further bleeding and 
surgery. The paper suggested that a visible vessel 
carried the greatest prognostic significance. Although 
the occurrence of further bleeding and mortality was 
entirely restricted to ulcers with visible vessels, it is 
important to note that in this study only half these 
patients had further bleeding.
Harris and Heap (1982) reported a retrospective study 
on the significance of SRH. Two hundred and eighty 
three urgent endoscopies were performed for bleeding in 
269 patients. One hundred and thirty one had bleeding 
peptic ulcer (57 gastric, 69 duodenal). Of the duodenal 
ulcer patients, 52 had SRH of whom 23% rebled and 29% 
required surgery; 17 had no SRH and 12% rebled and none 
had surgery. Of the gastric ulcer patients, 44 had SRH 
of whom 31% rebled and 25% had surgery; 13 had no SRH and 
none rebled or had surgery. However, not all studies
of the prognostic significance of SRH are consistent. A 
recent report from the World Congress of Gastroenterology 
(Garrigues-Gil et al 1988) reviewed 207 patients 
presenting to a single centre with bleeding from an
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endoscopically proven duodenal ulcer. The authors were 
unable to conclude that SRH had any prognostic 
significance and that only active bleeding at the time of 
endoscopy was a significant indicator of the need for 
early surgery. They did, however, point out that their 
study contained small numbers of patients,
c) Endoscopy or Radiology?
An alternative investigational option is, of course, 
the barium meal. Prior to the general use of the 
endoscope, radiology employing barium was the major 
method in investigation of acute UGIT. A number of 
studies have compared radiology and endoscopy with the 
consensus favouring endoscopy. Hoare (1975) examined 
158 patients with UGIT and found that because the 
pre-operative diagnosis was correct in all endoscopy 
cases there was less delay before surgery. Mortality 
was improved and he felt that endoscopy was the 
investigation of choice. Similarly, Stevenson et al
(1976) compared double contrast barium meal and 
fibreoptic endoscopy prospectively in acute upper 
gastrointestinal bleeding in 53 consecutive patients. 
Bleeding site was correctly identified by endoscopy in 
94% and by radiology in 83%. In 50 patients with a 
definitive final diagnosis, endoscopy was correct in 100% 
and radiology in 88%. The trial was abandoned because of 
better endoscopy figures and endoscopy became the 
diagnostic method of choice. McGinn et al (1975)
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compared endoscopy and radiology in 150 patients with 
acute UGIT bleeding. One hundred and thirty eight 
patients had both endoscopy and barium meal. The 
combination of both methods gave a diagnostic accuracy of 
91%. They concluded that radiology seemed adequate for 
gastric or duodenal lesions whilst endoscopy was 
preferable for the oesophageal and mucosal lesions. More 
recently Thoeni and Cello (1980) prospectively examined 
100 patients with upper gastrointestinal bleeding with 
endoscopy and double contrast radiology. Endoscopy 
detected the primary bleeding site in 93% of patients and 
led to the correct diagnosis in 91% of all upper 
gastrointestinal lesions present. Radiography detected 
primary site in 80% and led to the correct diagnosis in 
76% of all upper gastrointestinal lesions. Endoscopy 
missed lesions in the duodenum and oesophagus most 
frequently whilst radiography missed oesophageal lesions 
most frequently. The two investigations combined gave an 
overall diagnosis accuracy of 99%. The authors
suggested that the two methods were complementary in 
acute bleeding from upper gastrointestinal tract. However 
it appears that endoscopy has become the prime method of 
investigation of these patients.
1.4 Treatment of upper gastrointestinal tract bleeding
A number of facts have been deduced from the 
literature. Although peptic ulcer disease is becoming a 
less frequent cause of hospital admission, there is no
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clear evidence, as yet, that UGIT bleeding is becoming 
rarer. What is clear is that the average age of patients 
presenting with this problem is increasing and that 
mortality is higher in this elderly age group. Patients 
with clinical evidence of severe or prolonged bleeding, 
as judged by shock or anaemia, have a poor outlook. Early 
diagnosis by endoscopy may give useful information in a 
few cases as to the likelihood that the patient requires 
surgery but continuous bleeding may be a better indicator 
than evidence of recent bleeding. Once it has been 
determined that the patient falls into a poor prognostic 
group, how then is he to be treated? There are 
basically two possibilities: the physical methods -
surgery, and direct coagulation of the bleeding vessels 
and pharmacological methods.
1.4.1 Surgical treatment of UGIT bleeding
Conventional surgical treatment with ligation of 
bleeding vessels is obviously the definitive option where 
bleeding is uncontrolled by other means. Reference has 
already been made to the mortality associated with 
surgery in a number of studies. Mortality is always 
higher in elderly patients for obvious reasons of 
intercurrent disease. Most interest in the surgical 
option in the past few years has centred round the 
importance of early surgery particularly in the elderly 
group.
Morris et al (1984) studied 147 patients with proven
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duodenal or gastric ulcer who were randomised after 
stratification for age and site of ulcer to early or
delayed surgical management. The criteria for entry to 
the early group were 4 units blood or plasma to correct 
acute blood loss in 24 hours, one rebleed, or endoscopic 
stigmata. The delayed policy group required 8 units 
blood or plasma expander required to correct acute blood 
loss in 24 hours, had two rebleeds in hospital or 
persistent bleeding requiring transfusion of 12 units in 
48 hours or 16 units in 72 hours.
One hundred and forty two patients (42 patients aged 
under 60, 100 patients aged over 60) satisfied the
criteria for analysis. The early and delayed groups in
each category were well matched for age, sex, pulse, 
blood pressure and haemoglobin.
In patients aged under 60 there were no deaths in the 
group receiving early treatment. The groups were closely 
similar for all prognostic features. One hundred patients 
aged 60 or over were randomised to early or delayed
management. The overall mortality among all 142 patients 
in the study was 7% (10 deaths) all of the deaths
occurred in patients over 60 so that the mortality rate 
in these patients was 10%. Analysis of mortality in 
patients over 60 on an intention to treat basis gave a 
rate of 4% (two deaths) in the early group and a rate of 
15% (eight deaths) in the delayed group.
The conclusion of this trial was that for patients
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over 60 an aggressive surgical policy is associated with 
a significant reduction in mortality.
This group has recently published a review of 342 
further duodenal or gastric ulcer patients in whom their 
policy of early surgery has been applied. A mortality of 
6% in the over sixties patients was achieved (Wheatley et 
al 1990).
The importance of early surgery in patients liable to 
rebleed is relevant to the foregoing discussion on 
endoscopy and its apparent failure in some studies to 
effect a reduction in mortality (Dronfield et al 1977, 
Eastwood et al 1977, Graham 1980). A fall in mortality 
would not be expected unless early endoscopy was allied 
to a policy of early, appropriate surgical intervention. 
This view is supported by the work of Hunt and colleagues
(1977). They studied 728 patients in the period
1972-1977 and compared these to 588 patients in the 
period 1977-1982. They found a reduction in mortality 
in each diagnostic subgroup in the later period of the 
study. Only in the gastric ulcer group, however, did this 
reduction reach statistical significance. They claimed 
that their achievement was due to the introduction of a 
special unit for treatment of upper GIT bleeding with a 
policy of early intervention.
Himal et al (1978) reported a similar result in 
Montreal when they compared two series of 1963-1971 and
1973-1976. They found that there was a significant
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reduction in mortality from 12.5% to 6.7% when peptic 
ulcer patients were compared. However there was no 
significant reduction in mortality in varices patients. 
The authors suggested that the improvement seen in the 
total series and in ulcer patients specifically was due 
to more aggressive surgical intervention.
It can be tentatively claimed, therefore, that 
advances in the diagnosis and early detection of high 
risk individuals with subsequent aggressive management by 
special units may lead to reduction of ulcer related 
mortality.
1.4.2 Physical methods of treatment
a) Cautery
Several physical methods of controlling GI bleeding 
have been investigated using a variety of modalities. 
Lyano acrylic tissue glues have failed experimentally 
(Protell et al 1978) and the spraying of clotting factors 
on the sites of haemorrhage is unlikely to be effective 
for brisk haemorrhage (Linscheer et al 1979).
Diathermy, applied endoscopically, although effective 
in arresting acute haemorrhage, by causing deep and 
unpredictable tissue injury, and is not suitable for 
clinical use (Dennis et al 1979).
Heater probes, which apply heat directly to the 
bleeding vessel, have been used effectively in the 
control of acute bleeding in gastric ulcers (Storey et al 
1983) but have not been widely used in clinical
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practice.
Kernohan et al (1984) carried out a controlled study 
of bipolar electrocoagulation in patients with upper 
gastrointestinal bleeding. They did not show that 
bipolar electrocoagulation reduced the incidence of 
rebleeding in upper gastrointestinal haemorrhage.
Johnstone et al (1982) treated patients with upper 
gastrointestinal bleeding by monopolar
electrocoagulation. They produced full thickness muscle 
layer damage in 16 of 30 ulcers (53%) and grossly visible 
serosal change of haemorrhage or whitening overlying the 
ulcer was found at autopsy in 14 of 30 (47%).
b) Laser Photocoagulation
Blue-green Argon laser light is preferentially 
absorbed by blood and thus can potentially induce 
clotting and sealing of blood vessels with less damage to 
surrounding tissue than other lasers used for 
haemostasis. However, blood which overlies the target 
vessel is an effective barrier to transmission of Argon 
energy. The addition of a coaxial C02 gas jet to blow 
away overlying blood greatly improves the efficacy of 
Argon treatment (Silverstien et al 1979; Fruhmorgen et al 
1976). Animal studies by Johnston et al (1981) have 
shown that this laser is safe and effective when used 
endoscopically providing the stomach is not 
over-distended by the carbon dioxide jet required to 
clear blood.
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Laurence et al (1980) studied the Argon laser in a 
clinical setting and found it effective in arresting 
haemorrhage in 48 of 60 patients bleeding from gastric or 
duodenal ulcers. Laser photocoagulation was seen to stop 
arterial (spurting) bleeding at endoscopy in 25 of the 36 
patients.
Similarly, Swain et al (1981) studied 76 randomized 
controlled patients with bleeding from peptic ulcer. They 
showed that Argon laser photocoagulation can 
significantly reduce mortality from bleeding peptic 
ulcers accessible to this form of treatment. They also 
demonstrated a significant reduction in rebleeding rate, 
and 7 deaths occurred in patients in the control group 
who had rebled, but there were no deaths in the treated 
group. Treatment however did not significantly reduce the 
rebleeding rate in the small group of patients actively 
bleeding from visible vessels.
Vallon et al (1981) studied 136 patients with 
bleeding from gastric and duodenal ulcers who were 
randomly allocated to Argon laser photocoagulation. There 
were no statistically significant differences between the 
laser treatment and control groups in terms of 
rebleeding, the need for surgical intervention, or death.
The Neodymium Yttrium aluminium garnet laser has a 
wavelength near infra-red and at effective haemostasis 
energy levels, the depth of penetration of this invisible 
laser beam is greater than the Argon laser. The Nd YAG 
laser energy is absorbed by haemoglobin. However, this
-  50 -
absorption is far less efficient than with the Argon 
laser and its energy is more widely scattered and is 
mostly absorbed by water and tissue proteins and is 
converted to heat. The deeper penetration makes it 
haemostatically effective although animal experiments 
have demonstrated that it has the potential for full 
thickness injury (Silverstein et al 1981).
Vantrappen et al (1981) carried out a controlled 
trial of Nd YAG laser photocoagulation in 227 patients. 
They were able to coagulate all bleeding lesions and 
showed a significant reduction in rebleeding rate but not 
in mortality rate. In another study by Rutgreerts et al 
(1982), in which 338 patients with bleeding upper 
gastrointestinal tract were entered, 23 patients who had 
presented with spurting arterial bleeding were treated by 
laser. The bleeding ulcer was localized in the stomach in 
13 patients and in the duodenum in 10 patients. In 20 
patients (87%), the bleeding could be stopped by laser. 
The haemastasis was permanent in 9 of the 20 patients 
(45%) whereas 11 of the 20 patients (55%) had recurrent 
haemorrhage after an interval of 1-36 hours (mean 12 
hours). Fourteen of the 23 patients (61%) had to be 
operated on. Overall mortality in the group of arterial 
spurters amounted to 7 out of 23 (30%).
MacLeod et al (1983) studied in a prospective single 
blind controlled trial the efficacy of the Nd YAG laser, 
significantly reduced the rate of rebleeding and need for 
emergency surgery in those patients with active bleeding.
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Regardless of whether allocated to placebo or laser 
treatment, none of the 25 patients bleeding from gastric 
and duodenal ulcers with spots in the ulcer base had 
further bleeding, required emergency surgery or died. 
However, only a small proportion of haemaemesis patients 
were deemed suitable for laser treatment in this study.
Swain et al (1986) examined the efficacy of Nd YAG 
laser photocoagulation in treatment of bleeding from 
peptic ulcer. Two hundred and sixty patients with 
bleeding peptic ulcer of whom 138 patients had stigmata 
of recent haemorrhage were randomized to be treated by 
laser or sham treatment.
The results of this trial suggests that the NdYAG 
laser significantly reduced the rebleeding rate, the need 
for emergency surgery and mortality. Fifteen of 31 
patients rebled in the control group and 4 of 28 patients 
rebled in the treatment group.
Rutgreerts et al (1987) studied in a randomized trial 
the efficacy of BICAP electrocoagulation and Nd YAG laser 
photocoagulation. The study was carried out on 100 
patients presenting at endoscopy with peptic ulcers and 
spurting or oozing vessel or a non-bleeding vessel. All 
patients received pretreatment with injection of 1:10,000 
adrenaline around the ulcer.
In the group with spurting haemorrhage, the BICAP was 
more effective than laser although the difference between 
the two groups was not significant. Emergency surgery was 
required in three patients who presented with arterial
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bleeding in the laser group and one in the BICAP group. 
Nd YAG laser induced arterial spurting from a
non-bleeding vessel in 5 patients despite previous 
injection therapy and laser therapy allowed haemastasis 
in 3 of these patients. Two patients developed a
perforation: 1 patient after laser therapy and another
patient after BICAP therapy. The authors concluded that 
both treatment methods were equally effective.
The importance of these physical methods of treatment 
can therefore be summarised. Surgery remains the final 
option in management. When bleeding cannot be controlled 
by other means, surgery is required. It is associated 
with a high mortality and is expensive. Knill Jones and 
colleagues (1990) have recently produced figures which 
indicate that surgery for UGIT haemorrhage in patients on 
non steroidal anti inflammatory drugs might cost #2000 
per episode. Non operative treatment which might allow 
patients home earlier than might have been the case if 
they required surgery is clearly preferable in a time of 
financial stringency.
The methods dependent on coagulation seem to have a
less clearly defined place in management. It appears 
that laser or electrocoagulation is good at stopping 
bleeding but not so good at providing a long term 
solution. The rebleeding rate seems unaffected by the 
treatment. This type of therapy may find its place as a 
"first aid procedure" providing temporary control of 
haemorrhage in unstable patients. The fact that
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successfully coagulated vessels have a tendency to 
rebleed indicates some possibilities for medical therapy. 
The clot may be dissolved by gastric acid or by natural 
fibrinolysis and drugs which might prevent this happening 
have been investigated.
1.5 Medical Treatment for Upper Gastrointestinal
Bleeding
(a) Cimetidine/Ranitidine
The development of drugs that specifically block 
the H 2 receptors for histamine (Black et al 1972) has 
provided a powerful pharmacological tool for control of 
gastric acid and hence treatment of peptic ulcer. H 2 
receptor antagonists inhibit gastric acid output 
stimulated by histamine, gastrin, or the vagal pathway 
and suppress meal-stimulated acid output (Pounder et al 
1976).
Cimetidine has been used widely in the treatment of 
patients with haematemesis and melaena. Many studies of 
the use of receptor blockers in upper GIT haemorrhage 
have been carried out and several of these have shown a 
benefit of such treatment.
Hoare et al (1979) studied 34 patients bleeding from 
peptic ulcer and given cimetidine while 32 patients were 
given placebo. Further bleeding was detected clinically 
in 24% (8/34) of the treated patients and 47% (15/32) in 
the placebo group. Cimetidine had no effect on bleeding 
from duodenal ulcer, but only 2 of 14 patients with 
gastric ulcer treated with cimetidine rebled, compared
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with 10 of 19 patients on placebo. Cimetidine, 
therefore, may help to prevent haemorrhage from gastric 
ulcer but not duodenal ulcer. Emergency operations for 
bleeding ulcers were needed in 4 patients in the 
cimetidine group and 3 patients in placebo group. One 
patient on cimetidine and 8 on placebo had emergency 
surgery for a bleeding gastric ulcer. Only one patient 
died. He had a duodenal ulcer and was on cimetidine. The 
number of patients with moderate or severe bleeding who 
subsequently rebled was not significantly different when 
treated and untreated groups were compared.
Stiel et al (1984) studied 55 patients with acute
bleeding from chronic duodenal ulcers. Twenty nine
patients received cimetidine and 26 received a placebo. 
Rebleeding rate in cimetidine treated patients was 17% 
(5/29) and 42% (11/26) with placebo treatment. Emergency 
surgery was required in 10% (3/24) of cimetidine treated 
patients and 14% (4/26) in placebo treated patients.
Cimetidine appeared to influence favourably the course of 
haemorrhage in patients over the age of 60 years with 
bleeding from duodenal ulcer with signs of recurrent 
haemorrhage.
Some studies however have not found a beneficial role 
for H 2 receptor blockade in upper GIT bleeding.
La Brooy et al (1979) studied 101 patients with upper
gastrointestinal tract bleeding. Peptic ulcer was the 
most common diagnosis. Rebleeding occurred in 21.5%
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(11/51) of the patients on cimetidine and 24% (12/50) of 
patients on placebo. The incidence of rebleeding in 
patients with peptic ulcers showed that cimetidine was 
not significantly better than placebo. The only one 
(2%) death in the series received cimetidine.
Similarly, studies by Siddiqi et al (1979), 
Carstensen et al (1980), Carr-Locke et al (1984) and 
Birnie et al (1984) have failed to show any significant 
improvement in rebleeding rate or mortality with 
cimetidine. The studies by Carr-Locke and Birnie die 
however suggest a trend for reduced recourse to surgery 
in the cimetidine treated group.
Some randomised trials have found that placebo groups 
have done better than cimetidine treated patients in 
terms of mortality, rebleeding and emergency surgery.
For example, Macklon et al (1979) found that when 30 
patients had completed their trial there had been an 
overall rebleeding rate of 20%. Of patients on 
cimetidine, 5 (28%) rebled compared with 1 (8%) out of 12 
on placebo.
Other studies by Pickard et al (1979), Meredith et al 
(1980), and Zuckerman et al (1984) have produced similar 
results.
Rantidine is approximately four times as potent an 
inhibitor of gastric acid output on a molar basis as 
cimetidine. Focon and colleagues (1980) studied the 
effect of ranitidine on bleeding of the upper
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gastrointestinal tract. Six patients were treated by
rantidine and 5 patients received placebo. In the 
treated group one patient rebled and none required 
surgery or died. In the placebo group, no rebleeding
occurred or no surgery was required and none died.
Hostein et al (1982) also studied the effect of rantidine 
in patients with upper gastrointestinal bleeding. Ten 
patients were in a treated group and 12 patients received 
placebo. In the treatment group, one patient had 
persistent bleeding, no surgery was required, and one 
died. In the placebo group, three patients persisted in 
bleeding, two patients required surgery and one patient 
died. Rantidine had a more significant effect on 
rebleeding, the need for surgery and the mortality rate.
It can be concluded from these studies that small 
numbers of patients recruited into trials have prevented 
clear cut answers from being obtained. The effects of 
H 2 receptor antagonists are probably marginal therefore,
(b) Somatosatin
Somatostatin has been shown to be a potent inhibitor 
of gastric acid secretion and gastrin release (Bloom et 
al 1979). It also inhibits the pentagastrin stimulated 
gastric secretion of acid, pepsin and intrinsic factor 
in in man (Schrumpf et al 1978). The peptide inhibits 
both basal and hormone induced secretion, when 
administered by the intravenous routes and basal gastric 
secretion when administered intragastrically (Johansson
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et al 1978). It also has a stimulative effect on gastric 
mucous production (Johansson and Aly 1982). Splanchnic 
blood flow decreases after intravenous infusion of 
somatostatin (Keller et al 1978; Tyden et al 1979).
Magnusson and colleagues (1985) have studied the 
effect of somatostatin in treatment of massive upper 
gastrointestinal bleeding in a randomised double-blind 
trial in 95 patients. Patients with oesophageal varices 
were excluded as well as patients with diabetes. Forty 
six patients, chosen at random, were given a 72 hour 
infusion of somatostatin, while the remaining 49 patients 
received an infusion of placebo. On the day after 
admission, an additional endoscopy was performed at which 
8 patients in the somatostatin group and 16 in the 
placebo group were found to have persistent bleeding. A 
total of 5 patients in the somatostatin group and 14 in 
the placebo group underwent surgery. Mortality rate did 
not differ significantly between the two groups.
Coraggio and colleagues (1984) compared the effects 
of somatostatin with ranitidine and placebo in a 
randomised fashion. Patients were allocated to one of 3 
groups. The first group received an intravenous 
injection of 250 mg somatostatin followed by continuous 
infusion of 250 mg/hour with a peristaltic pump. The 
second group received ranitidine and the third group 
placebo. There were 20 patients in each group. The 
haemorrhage stopped in all the 20 patients treated with 
somatostatin, 13 of 20 patients treated with ranitidine
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and 9 of the 20 patients treated with placebo also had 
their haemorrhage controlled.
Moreover, no patient treated with somatostatin rebled 
while rebleeding occurred in 3 of the 13 patients treated 
with rantidine and in 2 of 9 patients treated with 
placebo.
Kayasseh et al (1980) also carried out a double-blind 
trial of somatostatin comparing it with cimetidine in the 
treatment of severe and persistent gastrointestinal 
bleeding due to peptic ulcer. Of the 20 patients 
studied, 10 patients received somatostatin and 10 
patients received cimetidine. Bleeding stopped in 8 out 
of 10 patients treated with somatostatin but in only one 
patient treated with cimetidine. One out of 5 patients 
rebled 24 hours after somatostatin treatment had ended 
and responded to a second course of somatostatin. 
Emergency surgery was required in one patient in the 
somatostatin group and in 5 patients in cimetidine group. 
No patients died in the somatostatin group but 3 patients 
died after receiving cimetidine
(c) Prostaglandins
Prostaglandins are compounds derived from fatty acids 
that are found throughout the body. They possess 
properties that make them uniquely suited for treatment 
of acute upper gastrointestinal tract haemorrhage. First, 
they inhibit gastric acid production resulting from a 
number of stimuli in both animals and humans (Robert et 
al 1975). In addition, they are cytoprotective in
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several animal models and can prevent the development of 
gastritis and subsequent bleeding caused by stress, 
shock, aspirin (Konturek et al 1981), indomethacin, 
absolute alcohol and concentrated hydrochloric acid 
(Cloud et al 1982; Main et al 1977). In humans they have 
been shown to be effective in preventing the 
gastrointestinal blood loss that frequently accompanies 
indomethacin therapy for rheumatoid arthritis (Johansson 
et al 1979). Several studies have addressed the 
question of the efficacy of prostaglandin in controlling 
acute gastrointestinal tract bleeding caused by 
duodenitis, gastritis, gastric erosions, gastric ulcers, 
or duodenal ulcers.
For example, prospective, randomised, double-blind 
study of the effectiveness of topical prostaglandins E 
(PGE2) in altering the outcome in patients with severe 
upper gastrointestinal tract haemorrhage was carried out 
by Levine and colleagues (1985).
Of the total of 44 patients entered into the study, 
22 patients were randomly allocated to receive either 
placebo or PGE2* Nine out of 22 patients were 
considered treatment failures in the placebo group. Three 
of these patients had persistent bleeding while 6 had 
recurrence of haemorrhage during the study. Eleven out of 
22 patients in the PGE2 treated patients also failed the 
study. Five of these patients exhibited persistent 
haemorrhage, whereas haemorrhage recurred in 6 during the 
study period. Emergency surgery was required in 9
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patients and these included 5 in the placebo group and 4 
in the PGE2 patients.
It may be concluded, therefore, that the role of acid 
reducing drugs in the management of UGIT bleeding is far 
from clear. Somatostatin appears to be effective in 
stopping bleeding and preventing rebleeding but it is 
expensive and requires to be given by intravenous 
infusion. A clear role for H2 receptor antagonists has 
not really been supported by the published studies and it 
has not been clearly shown that prostaglandin analogues 
have a beneficial effect in established bleeding. The 
role of antifibrinolytic drugs will now be considered,
d) Antifibrinolytic therapy
If clot has developed in a vessel in the base of an 
ulcer, it may be dissolved by gastric acid or by natural 
fibrinolytic processes. As mentioned above, the evidence 
supporting a role for acid reducing drugs in the 
management of UGIT haemorrhage is far from convincing. 
The possibility that antifibrinolytic agents might reduce 
rebleeding, the need for surgery and subsequent mortality 
in these patients will now be examined.
Three very similar, double blind studies have been 
carried out on the effectiveness of tranexamic acid in 
treatment UGIT bleeding (McCormack et al 1973, Biggs et 
al 1976, Enggrist et al 1979). Each study consisted of 
about 150 patients randomly allocated to receive active 
drug or placebo. Trends, which were not significant, 
were observed in favour of the drug which appeared to
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reduce the number of patients requiring surgery. A much 
larger study, incorporating 775 patients was published by 
Barer and colleagues (1983). Patients received 
cimetidine, tranexamic acid or placebo. Again, no 
significant differences were observed but there was a 
clear trend towards reduced mortality in patients 
receiving tranexamic acid.
Another study including 150 patients was reported by 
Holstein et al (1987). In this case, the tranexamic 
acid group was observed to require significantly reduced 
amounts of blood and had significantly reduced operation 
and rebleeding rates. The dosages of the drug used in 
this study were identical to those used in the earlier 
studies and the different result may be a chance finding 
in a study which had inadequate numbers of patients.
Because of the small sizes of these individual 
studies, Henry and O'Connell (1989) performed a 
meta-analysis combining all their data. This showed 
significant reductions in both rebleeding and mortality 
with tranexamic acid treatment (table 1.1) supporting 
the theory that fibrinolysis plays an important role in 
UGIT bleeding.
1.6 Fibrinolysis
1.6.1 Development of Knowledge
It has been known for many years that human blood 
possesses fibrinolytic activity. Hunter (1794) records 
that in 'animals killed by lightning or electricity7 or
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in animals 'who are run very hard, and killed in such a 
state' the blood does not clot. A partial explanation 
for this phenomenon was found in 1906 by Morawitz, who 
noted that the blood from victims of sudden death 
contained no fibrinogen and could destroy the fibrinogen 
and fibrin of normal blood. Denis (1838) observed that 
the blood clots obtained in wet cupping redissolved in 
less than 24 hours. Green (1887) noted that when fibrin 
prepared from ox blood had dissolved when incubated in 
saline it could not be clotted again by thrombin. Dastre 
(1893), during the course of phlebotomy in dogs, observed 
a reduction of fibrin yield which he attributed to 
destruction of fibrin, a process which he named 
'fibrinolysis' and Hedin (1903) found spontaneous 
fibrinolytic activity in the globulin fraction of ox 
blood. A further addition to knowledge of spontaneous 
fibrinolytic activity in blood was finally obtained by 
Macfarlane (1937) who showed that in man fibrinolytic 
activity in the blood could be provoked by surgical 
operations.
Fibrinolytic activity in human blood may be derived 
either from blood cells (especially leucocytes), or from 
conversion of the circulating plasma protein plasminogen 
to the active enzyme, plasmin. There is currently much 
more knowledge of plasmin-mediated fibrinolysis than of 
cellular fibrinolysis (Bachmann, 1987), hence this review 
concentrates on the plasminogen-plasmin system which is 
outlined in Fig. 1.
-  64 -
Plasminogen, plasminogen activators, fibrinolytic 
inhibitors, and the degradation of fibrinogen and fibrin 
will now be reviewed in turn.
1.6.2 Plasminogen
(a) Synthesis and Metabolism
The physical properties, turnover, and activation of 
plasminogen have been summarised in several reviews
(Collen and De Maeyer, 1975; Collen and Verstraete, 
1975; Robbins, 1978; Bachmann, 1987). Human
plasminogen is a single chain glycoprotein with a
molecular weight of 88,000 (Wallen, 1978). It is 
synthesised in the liver. The plasma concentration of 
plasminogen is around 200 ug/ml (Collen et al 1972). Its 
half-life in healthy men is 2.2 days (Bachmann, 1987). A 
rapid rate of synthesis is inferred from the restoration 
of normal plasma concentrations within 12-24 hours of
depletion during thrombolytic therapy with
streptokinase.
(b) Structure and Properties
Human plasminogen is a single-chain glycoprotein with a 
molecular weight of 88,000, containing approximately 2% 
carbohydrate (Wallen et al 1978; Sjoholm et al, 1973; 
Wiman and Wallen 1975b). The single-chain molecule has 
glutamic acid (Wallen and Wiman, 1972; Rickli and 
Cuendet, 1972) and asparagine (Robbins et al, 1967) as 
NH^-terminal and C-terminal amino acids respectively. The 
plasminogen molecule consists of 790 amino acids, and it
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Plasminogen activators<---------- Anti-activators
AntiplasminsPlasminogen
Histidine-rich glycoprotein.
FibrinFibrinogen
Degradation products
Figure 1.1 The Fibrinolytic System (--- * Inhibitory
pathways)
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it contains 24 disulfide bridges and 5 homologous triple 
loop structures known as kringles (Wiman, 1978; 
Sottrup-Jensen et al, 1978). Native plasminogen has 
NH2-terminal glutamic acid ('Glu-plasminogen') but is 
easily converted by limited plasmic digestion to modified 
forms with NH2~terminal lysine, valine or methionine 
(Wallen and Wiman, 1970; Wallen and Wiman, 1972) which 
are commonly designated 'lys-plasminogen'.
Affinity chromatography on lysine-sepharose using 
gradient elution with 6-aminohexanoic acid separates 
plasminogen into two fractions, type I and type II, in 
order of their elution from lysine-sepharose (Brockway 
and Castellino 1972). The first form appears more 
easily activated than the second and has a larger Stokes 
radius, as evidenced by gel filtration (Collen and De 
Maeyer 1975). This heterogeneity is apparently due to 
differences in the composition of the carbohydrate side 
chains of plasminogen (Hayes and Castellino, 1979a, 
1979b, 1979c). Type I contains both a glucosamine-based 
oligosaccaride chain on Asp 288 and a galactosamine-based 
carbohydrate chain on Thr 345, while type II has only the 
latter. Each of these two fractions can be separated in 
6 isoelectric forms with differences in sialic acid 
content. It has been suggested that these carbohydrate 
side chains might play a role in the interaction between 
plasminogen and a 2-antiplasmin or fibrinogen (Lijnen et 
al, 1981; Bachmann, 1987).
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(c) Lysine-binding Sites
Structures in plasminogen which specifically bind 
omega amino-acids such as lysine and 6-aminohexanoic acid 
are termed the lysine-binding sites. The plasminogen 
molecule contains 5 of these lysine-binding sites: one
binding site with a high affinity for 6-aminohexanoic 
acid on kringle one and about 4 with low affinity on 
kringles 2-5 (Markus et al 1978; Bachmann, 1987). These 
lysine-binding sites are located in the plasmin A-chain 
(Rickli and Otavsky, 1975).
Plasminogen can specifically bind to fibrin through 
its lysine-binding sites. It has been found in a 
purified system (Thorsen, 1975) and in plasma (Rakoczi et 
al, 1978) that Lys-plasminogen has a higher affinity for 
fibrin than the intact Glu-plasminogen. The presence of 
6-aminohexanoic acid abolished the adsorption of 
plasminogen to fibrin both in the purified system 
(Thorsen, 1975) and in plasma (Rakoczi et al, 1978). Thus 
it is concluded that one of the functions of the 
lysine-binding sites, and mainly of the high affinity 
lysine-binding site (Hoylaerts et al, 1981), in 
plasminogen is to mediate its interaction with fibrin.
As will be discussed below, the lysine-binding sites 
of plasminogen also mediate its interaction with 
C^2-antiplasmin, which therefore is a control mechanism in 
fibrinolysis.
1.6.3 Plasminogen Activators
It has been proposed that endogenous activation of
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plasminogen can take place by two pathways, one extrinsic 
and the other intrinsic. In intrinsic plasminogen 
activation, all the components involved are present in 
precursor form in the blood. The extrinsic plasminogen 
activation system involves the release of tissue 
plasminogen activator (tPA) into the blood. From the 
physiological standpoint, the most important source of 
tPA is the vascular endothelium. The endothelial cells 
have the capacity to release tPA in response to some 
stimuli (stress, exercise, venous occlusion,
catecholamines, and vasopressin and its analogues) and in 
accordance with the continuation of the stimulus are able 
to synthesize further tPA as required (Todd, 1959; 
Pandofi et al, 1967; Cash, 1975; Bachmann, 1987). 
Venous occlusion and the vasopressin analogue, 
desmopressin, have been used as stimulation tests to 
measure the "fibrinolytic capacity" of subjects and 
patients (Bachmann, 1987).
a) Tissue-type Plasminogen Activator ftPA). was 
recognized to exist in many organs, tissues and 
secretions over 20 years ago (Astrup, 1966). Highly 
purified preparations were obtained from pig heart 
(Rickli and Zaugg, 1970; Cole and Bachmann, 1977; Wallen 
et al, 1978); human uterus (Rijken et al, 1979) and 
cultured human melanoma cells (Rijken and Collen, 1981). 
tPA from the latter source was used to develop specific 
assays, and also allowed cloning and expression of the 
cDNA for tPA in Escherischia coli (Pennica et al, 1983).
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The latter process has been used to produce tPA in 
sufficient quantities for clinical trials of thrombolytic 
therapy, e.g. in myocardial infarction (de Bono, 1987). 
The complete amino-acid sequence of tPA structure has 
also been defined (Bachmann, 1987).
tPA has a molecular weight of 68,000, and exists at a 
very low basal concentration in plasma (5 ug/ml; 
Bachmann, 1987). The molecule has two kringles, one of 
which has a lysine-binding site which gives it a high 
affinity for fibrin. Fibrin binds tPA and
Glu-plasminogen, allowing a very efficient activation of 
plasmin on the fibrin surface. Free tPA in plasma is 
rapidly bound by plasminogen activator inhibitor type I 
(PAI-1). These mechanisms therefore control extrinsic
fibrinolysis and tend to limit its action to fibrin 
(Bachmann, 1987).
(b) Urinary-type plasminogen activator
The intrinsic system of plasminogen activation 
involves the activation of the contact system 
(coagulation factor XII, high molecular weight kininogen, 
and prekallikrein) to form kallikrein, which then 
converts circulating single-chain urinary-type
plasminogen activator (scuPA, also called pro-urokinase) 
to two-chain urinary type plasminogen activator (tcuPA, 
also called urokinase). As with tPA, the amino-acid 
sequence of uPA and its cDNA nucleotide sequence have 
been determined, and it has been produced in sufficient 
quantities for clinical trials of thrombolytic therapy.
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uPA has a molecular weight of 54,000, and the basal 
plasma level is 2-20 ug/ml (Bachmann, 1987). As its 
name suggests, urokinase was first identified in urine 
(Sahli, 1885; Macfarlane and Pilling, 1947; Williams 
1951; Sobel et al, 1952). It was first isolated from 
human urine or cultured embryonic kidney cells (Bernik 
and Kwaan, 1967, 1969; Kucinski et al, 1968).
c) Streptokinase
This exogenous plasminogen activator is a non-enzyme 
protein. It is produced by the Lancefield group C 
strains of B-haemolytic streptococci, and activates the 
fibrinolytic system indirectly. Streptokinase complexes 
with plasminogen and thereby converts the inactive 
pre-enzyme into an efficient plasminogen activator. The 
properties and mechanisms of action of streptokinase have 
reviewed (Brogen et al, 1973; de Bono, 1987). In 
recent years thrombolytic therapy with streptokinase has 
been shown to reduce mortality in acute myocardial 
infarction, and this has reawakened clinical interest in 
fibrinolysis (de Bono, 1987).
1.6.4 Inhibitors of Fibrinolysis
The fibrinolytic inhibitors are of two main types: 
those which inhibit plasmin (plasmin inhibitors, 
antiplasmins) and those which inhibit plasminogen 
activation (antiactivators). Many substances have been 
shown to possess antiplasmin and anti-activator activity, 
including soy-bean trypsin inhibitor, amino acids such as 
lysine, 6-aminohexanoic acid, tranexamic acid, and
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aprotinin. The last three compounds have been used 
therapeutically.
a) Endogenous Inhibitors of Plasmin
Platelets and mesothelial cells contain antiplasmins, 
but these inhibitors are poorly characterised. There are 
at least 5 well defined proteins which inhibit plasmin in 
a purified system - namely Oi macroglobulin,
a 1-antitrypsin, inter-a -trypsin inhibitor, antithrombin 
III-heparin complex, and Cl-esterase inhibitor. The 
most important physiological inhibitor of plasmin formed 
in blood, is however a relatively recently described 
plasma protein called O' 2-antiplasmin (Hedner and 
Abilgaard, 1978). This inhibitor was independently 
identified by three groups (Collen 1976; Moroi and Aoki, 
1976; Mullertz, 1976). Upon activation of plasminogen in 
plasma, the formed plasmin is preferentially bound to 
a  2~antiplasmin. Only upon complete activation of 
plasminogen (concentration in plasma approximately 1.5 
umol/1) is the excess plasmin neutralised by 
c*2-macroglobulin. In the presence of normal
concentrations of these two inhibitors, the other plasma 
protease inhibitors do not play any role in the 
inactivation of plasmin. 
cl -antiplasmin
CK2-antiplasmin, the main physiological plasmin 
inhibitor in plasma, is a single chain glycoprotein of 
molecular weight 70,000 containing approximately 13% 
carbohydrate (Moroi and Aoki, 1976; Wiman and Collen,
-  72 -
1977). The concentration of -antiplasmin in pooled 
normal plasma is approximately 1 mM (Moroi and Aoki, 
1976; Mullertz and Clemmensen, 1976; Wiman and Collen, 
1977). The inhibitor is immunochemically different from 
the other known plasma protease inhibitors.
<2 2anti-plasmin forms a very stable 1:1 stoichiometric 
complex with plasmin which is devoid of protease or 
esterase activity (Moroi and Aoki, 1976; Mullertz, 1976; 
Wiman and Collen, 1977). The physiological role of 
o;2-antiplasmin as an inhibitor of proteases other than 
plasmin seems negligible (Edy and Collen, 1977; Ohlsson 
and Collen, 1977).
A structural analysis of the plasmin-O' -antiplasmin 
complex suggested that the stable complex is formed by a 
plasmin attachment at a specific leucyl-methoionyl 
peptide bond in the COOH-terminal portion of the 
inhibitor. A strong properly covalent bond is formed 
between the Carbonyl group of this specific leucyl 
residue in the inhibitor (Wiman and Collen, 1979). The 
turnover of 1251-labelled a 2-antiplasmin was studied in 
control subjects and in patients during thrombolytic 
therapy (Wiman and Collen 1979). In the control group 
a 2-antiplasmin had a plasma half life of 2.64 + 0.32 days 
and fractional catabolic rate of 0.53 ± 0.09 of the
plasma pool per day. During thrombolytic therapy the 
half life shortened to approximately 0.5 day as a result 
of formation of plasmin--antiplasmin complex. The long 
half-life of the plasmin- q-antiplasmin complex was
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confirmed by studying the turnover of the purified 
complex both before and during thrombolytic therapy in 
patients with thrombotic disease.
The normal concentration of a  - antiplasmin in pooled 
normal plasma is approximately 1 umol/1 (Moroi and Aoki, 
1976; Mullertz, 1976; Wiman and Collen, 1977).
The concentration may decrease to below 30% in severe 
cases of liver disease or intravascular coagulation 
(Aoki, 1979) but is normal in patients with 
cardiovascular, renal or malignant diseases. The 
inhibitor is temporarily exhausted during thrombolytic 
therapy with streptokinase (Teger-Nilsson et al, 1977) 
when measured enzymatically. Residual antigen may
however be found immunologically representing complexed 
or degraded inhibitor or both, a 2-antiplasmin is a weak 
acute phase reactant (Teger-Nilsson, 1977)i Possibly some 
of the Q^-antiplasmin in plasma is inactive (Mullertz and 
Clemmensen, 1976).
Histidine-rich Glycoprotein
This glycoprotein of M.Wt. 75,000 is a competitive 
inhibitor of plasminogen, reversibly binding to its 
high-affinity lysine-binding site. In plasma,
histidine-rich glycoprotein complexes with about 50% of 
plasminogen, reducing its availability for binding to 
fibrin. However its inhibition of this interaction is 
less effective than that of (X -antiplasmin (Bachmann, 
1987).
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b) Plasminogen Activator Inhibitors
These have only been characterised in the last 5 
years (Bachmann, 1987). Plasminogen activator inhibitor 
type I (PAI-1) is the major inhibitor of tPA and uPA in 
plasma, and has a molecular weight of 54,000. It is 
secreted by endothelial cells, platelets and certain 
tumour cells. It is a strong acute-phase reactant 
protein, and high plasma levels are formed after trauma 
or surgery and in many disease states such as infections, 
coronary artery disease, and recurrent venous 
thromboembolism (Bachmann, 1987; Kruithof, 1988). 
Plasminogen activator inhibitor type 2 (PAI-2) comes from 
the placenta, leucocytes and monocytes, and high plasma 
levels are observed during pregnancy. A few other 
antiactivators have recently been described (Bachmann, 
1987).
1.6.5 Physiology of Fibrinolysis
The physiological roles of the fibrinolytic system 
appear to be (a) maintaining the vascular system free of 
thrombotic occlusions; (b) maintaining the different 
exocrine ducts and the urinary tract free from fibrin 
deposits; and (c) participating in tissue repair.
In the circulation, levels of tPA and plasmin are 
both very low. Even if the level of tPA rises markedly 
(e.g. after strenuous exercise, or injection of 
adrenaline or desmopressin), little free plasmin is 
formed because it is rapidly inhibited by ajantiplasmin. 
However, if fibrin is present, tPA and Glu-plasminogen
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form a complex which facilitates the conversion of 
clot-bound plasminogen to plasmin. The clot-bound 
plasmin is partially protected from the action of 
circulating Qi^  antiplasmin, and therefore digests the 
fibrin. This in turn exposes additional binding sites 
for the fixation of Glu-plasminogen to fibrin (Bachmann, 
1987).
Several factors may modulate this process. PAI-1 is 
released from platelets and endothelial cells and may 
stabilize thrombi by inactivating local tPA. Protein C 
is a plasma protein which inhibits thrombin and hence is 
an endogenous anticoagulant; it also complexes with 
PAI-1, thereby reducing the inhibition of fibrinolysis by 
PAI-1 (Bachmann, 1987).
Degradation of Fibrinogen and Fibrin
When the fibrinolytic system is activated by fibrin 
formation, plasmin degrades insoluble fibrin to soluble 
fibrin degradation products (FDP). Plasmin may also 
degrade circulating fibrinogen to soluble fibrinogen 
degradation products. The products of fibrinogen and 
fibrin differ (Niewenhuizen, 1987). When plasmin
digests fibrinogen, the first fragments formed are X 
fragments from the A O' chain of fibrinogen and fragment 
1-42 from the B|6 chain. Subsequently, X fragments are 
cleaved asymmetrically to give one Y fragment and one D 
fragment; then Y fragments are cleaved to give another D 
fragment and one E fragment. Fibrin differs from 
fibrinogen in that it has been cross-linked by factor
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XIII, hence its degradation products include cross-linked 
fragments such as X-oligomers and D-dimer (Niewenhuizen, 
1987).
1.6.6 Measurement of the Fibrinolytic System in Plasma 
(Lowe and Prentice, 1980)
a) - Plasminogen can be measured in plasma either 
immunologically or by its activity on various substrates 
(e.g. chromogenic substrates) after activation (e.g. by 
streptokinase). Q; -antiplasmin can also be measured
either immunologically or by its activity against 
activated plasminogen.
b) - Plasminogen activators can be measured in blood or 
plasma after removal of circulating inhibitors, which is 
usually performed by dilution and/or acidification to 
precipitate the euglobulin fraction, which contains 
plasminogen and plasminogen activators. Global 
plasminogen activators are usually measured by the dilute 
whole blood clot lysis time, the euglobulin clot lysis 
time, or the lysis area produced by drops of euglobulin 
fraction applied to fibrin plates (fibrin plate lysis 
area, FPLA). The latter method has the advantage over 
clot lysis times in that it is not affected by the 
patients' plasminogen or fibrinogen levels. Recently, 
specific assays of tPA activity and antigen have become 
available, as have assays of PAI-1 activity and antigen. 
Because PAI-1 is present in the euglobulin fraction, it 
has recently been appreciated that it is a major 
determinant of apparent plasminogen activator activity
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(Kruithof, 1988).
Fibrin degradation products (FDP) were traditionally 
measured by estimation of fibrinogen-related antigen in 
serum, which contains non-clottable FDP (e.g. D and E 
fragments) but not clottable fibrinogen or FDP (e.g. X 
and Y fragments). A commonly-used assay is the Wellcome 
FDP kit which uses the tanned red cell haemagglutination 
inhibition immunoassay method. A rapid,
semi-quantitative latex test is also available 
(Thrombo-Wellcotest) (Lowe and Prentice, 1980). In 
recent years, the use of such serum assays has been
criticised, because of false high levels due to formation 
of FDP during clotting of the plasma sample to obtain 
serum; false low levels due to trapping of FDP in the
clot; and insensitivity (Niewenhuizen, 1987). The
recent production of monoclonal antibodies against 
degradation products of both fibrinogen and cross-linked 
fibrin has allowed sensitive assays to be performed in 
plasma, as well as the differentiation of fibrinogen 
degradation from degradation of cross-linked fibrin 
(Niewenhuizen, 1987).
1.6.7 Pathological Fibrinolysis
In arterial and venous thrombosis, the formation of 
fibrin results in activation of the fibrinolytic system 
as shown by raised levels of both FDP and cross-linked 
fibrin degradation products (Whitaker et al, 1987). Some 
patients with premature or recurrent thrombosis have a 
low "fibrinolytic capacity", due either to low release of
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tPA from vascular endothelium, or to high levels of PAI-1 
(Bachmann, 1987). Marked systemic activation of
fibrinolysis occurs in disseminated intravascular 
coagulation and following streptokinase infusion, as 
shown by depletion of fibrinogen, plasminogen and 2 
antiplasmin, and high levels of both FDP and cross-linked 
fibrin degradation products (Whitaker et al, 1987). A 
generalised bleeding tendency occurs in such patients.
Localized bleeding may also be influenced by 
localized fibrinolysis. This is suggested by the value 
of fibrinolytic inhibitor drugs (e.g. epsilon
aminocaproic acid, tranexamic acid) in several clinical 
situations. These include menorrhagia, subarachnoid 
haemorrhage, bleeding after dental extraction in 
haemophilia, and gastro-intestinal bleeding (Davidson, 
1980; Verstraete, 1987, Henry and O'Connell, 1989). The 
role of fibrinolysis in upper gastrointestinal bleeding 
is the subject of the present thesis, and is reviewed in 
the next section.
1.7 The Upper Gastrointestinal Tract and Fibrinolysis
The fibrinolytic system acts as a defence system in 
several different ways. It helps keep the vascular 
system free of thrombotic occlusions, and in a similar 
manner it keeps different exocrine ducts and the urinary 
tract free from fibrin deposits. In addition, local 
fibrinolysis probably plays an important role in tissue 
repair. The presence of fibrinolytic activity in the 
gastro-intestinal tract (Poller, 1979), is therefore not
- 79 -
surprising.
The possibility that excess fibrinolysis can be an 
aggravating factor in peptic ulcer bleeding has been 
suggested. Cox et al (1967) studied gastric
fibrinolytic activity by taking blood directly from 
gastric and peripheral blood vessels in patients with a 
peptic ulcer and in a parallel control group. The
parallel series of patients studied over the same period 
was a mixed group who had undergone an upper abdominal 
operation, and from whom blood could therefore be 
obtained from similar gastric vessels. These patients 
had a normal stomach and duodenum and had had an 
operation for gall bladder stones. Free plasmin was 
found in the gastric vein, plasminogen activator in the
mucosa, and fibrinolytic activity in the gastric juice.
Eleven out of 13 patients with a peptic ulcer had free 
plasmin in their gastric vein, but this activity was
present in only 5 out of 13 patients from the parallel 
group. The conclusion was that fibrinolysis in the 
stomach and duodenum was greater in these patients who 
had a peptic ulcer than those who had not (Cox et al, 
1967). However this was not confirmed by O'Brien et al 
(1979) who showed that the fibrinolytic activity of blood 
draining from the stomach of patients with gastroduodenal 
disease was comparable with the fibrinolytic activity of 
blood draining from normal stomach. Gastric venous 
blood from normal and diseased stomachs contains greater 
amount of plasminogen activator than simultaneously
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sampled systemic venous blood. However, gastric venous 
fibrinolytic activity does not differ between the normal 
and diseased stomachs.
In a further study, Cox et al (1969) looked for 
evidence of the release of gastric fibrinolytic activity 
into peripheral blood after trauma on the stomach. The 
study was performed on patients who had undergone 
laparotomy. The first step in the procedure was to pick 
up the stomach and to exert pressure on the anterior and 
posterior walls by compression between the fingers and 
thumb, the finger anterior to the anterior wall and the 
thumb posterior to the posterior wall from the pylorus to 
the fundus. This took 30 seconds. Gastric venous 
specimens were taken immediately after this gastric 
compression, all the specimens being obtained within 5 
minutes. The aim in each case was to take 3 specimens 
from each patient. In all patients 3 specimens of 
peripheral venous blood were taken at 10 minute 
intervals; the first peripheral venous specimen was 
taken at the same time as the first gastric vein 
specimen. Fibrinolytic activity in peripheral venous 
blood and its progressive rise following gastric 
compression, was observed. It is reasonable to assume 
that the lytic activity released from the stomach would 
have reached the arm vein in sufficient concentration 
within 10 minutes.
Eras and colleagues (1970) studied plasmin activator 
in the stomach, using samples obtained at surgery from
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patients operated on for duodenal ulcer disease. In one 
patient, additional specimens were obtained from the 
gastric fundus, antrum, and duodenum. These specimens 
were taken from an area which appeared grossly normal. 
Plasminogen activator activity was localized in gastric 
and duodenal tissue using histological techniques. 
Plasminogen activator activity was then studied in 
relation to mucosal and submucosal blood vessels in 
selected tissues. Proteolytic activity was identified in 
the surface epithelium of the stomach and duodenum.
Kondo et al (1975) studied the distribution of the 
fibrinolytic activity in gastric ulcers. In humans 
gastric ulcer mucosa was surgically removed from patients 
with gastric or duodenal ulcers and was examined for the 
distribution of fibrinolytic activity. Fibrinolysis was 
found in cases with an acute episode of gastric ulcer. 
The activity was seen to be localized around the ulcer as 
well as the eroded lesion. In the stomach of those 
patients developing massive haemorrhage after a long 
history of gastric ulcer, tissue fibrinolysis was 
detectable only in those parts close to the ulcer.
A further study reported that high concentrations of 
systemic serum F.D.P. were also associated with recent 
gastrointestinal haemorrhage (Poller and Thomson, 1969). 
Subsequently, Poller (1979) studied patients with 
haematemesis and melaena, and compared them with patients 
bleeding in other sites, most of whom were suffering from 
menorrhagia or having operations. The concentrations of
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serum F.D.P. in haematemesis and melaena patients were 
significantly higher than in other groups, suggesting 
increased systemic fibrinolysis (Fig 1.2).
Because this increased fibrinolysis may play a role 
in acute upper gastrointestinal bleeding, several trials 
of fibrinolytic inhibitor drugs have been performed in 
this clinical situation as noted in Section 1.3.
Taken together, these studies suggest that tranexamic 
acid may be beneficial in acute upper gastrointestinal 
bleeding (Henry and Collins 1988), although it does not 
yet appear to have become routine therapy for this 
condition. They also support the hypothesis that 
excessive fibrinolysis may promote bleeding in this 
situation.
One way to test this hypothesis is to measure 
fibrinolytic activity in patients hospitalized with acute 
upper gastrointestinal bleeding, and to relate such 
measures to the outcome (i.e. further bleeding requiring 
blood transfusion or surgery, or resulting in death). 
Such a natural history study has not been performed. The 
aim of the first study reported in this thesis was to 
relate certain tests of systemic fibrinolysis to such 
outcomes in a large series (over 100) of patients with 
acute upper gastrointestinal bleeding. The tests chosen 
were (a) serum FDP, measured quantitatively by the 
Wellcome FDP kit (Lowe and Prentice, 1980). Serum FDP 
have been shown to be elevated in acute upper 
gastrointestinal bleeding although their prognostic
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significance has not been explored (Poller, 1979) and (b) 
total plasminogen activators, measured quantitatively by 
the fibrin plate lysis area test (Lowe and Prentice,
1980), which had been shown to be increased in systemic 
blood by local compression of the stomach (Cox et al, 
1969). Following the demonstration that serum FDP were of 
prognostic value, retrospective testing on remaining 
serum samples was performed to determine (c) whether the 
simple, semiquantitative latex serum FDP test 
(Thrombo-Wellcotest, Wellcome) was of prognostic value; 
and (d) whether plasma cross-linked fibrin degradation 
products (Dimertest ELISA, AGEN) were of prognostic
value. These tests were also related to the site of
bleeding and the bleeding lesion, as shown by endoscopy.
No previous study has investigated these associations.
1.8 Oesophageal Varices and Fibrinolysis
Excessive fibrinolysis may be especially important in 
the pathogenesis of one particular type of upper 
gastrointestinal bleeding i.e. bleeding from oesophageal 
varices in patients with hepatic cirrhosis. Such 
patients have several defects in haemostasis (Brozovic, 
1987). These include thrombocytopenia, impaired hepatic 
synthesis of clotting factors; synthesis of structurally 
abnormal fibrinogen and other clotting factors; 
disseminated intravascular coagulation; impaired hepatic 
clearance mechanisms; and abnormal fibrinolysis 
(Brozovic, 1987). The normal liver synthesises
plasminogen and qj- antiplasmin, and is the site of
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clearance for plasma plasminogen activators, FDP, and 
other breakdown products which may activate fibrinolysis 
(Brozovic, 1987). In cirrhosis, low plasminogen levels 
might theoretically decrease fibrinolytic potential; 
however there is usually enhanced fibrinolysis as shown 
by decreased 0L2 antiplasmin and increased plasminogen 
activator levels due to impaired clearance (Brozovic, 
1987), and increased serum FDP (Bertaglia et al, 1983).
Bertaglia et al (1983) found higher levels of serum 
FDP among patients with cirrhosis in those who had 
bleeding oesphageal varices.
In the second study reported in this thesis, the aim 
was to study further the role of fibrinolysis in bleeding 
from oesophageal varices by measuring systemic 
fibrinolysis (again by fibrin plate lysis area and serum 
FDP tests) in patients with oesophageal varices, and 
relate these tests to prognosis, as well as to the 
Child's grade of severity.
1.9 Conclusions and Aims of Study
(1) Acute upper gastrointestinal bleeding remains a 
common medical emergency with a significant mortality, 
requiring further research into its pathogenesis and 
treatment.
(2) Excessive fibrinolysis may play a role in 
pathogenesis, however no prospective studies of 
fibrinolysis have been performed to test this 
hypothesis.
(3) The aims of the studies reported in this thesis were
-  86 -
as follows:
(a) to measure systemic fibrinolytic activity (total 
plasma plasminogen activators by the fibrin plate assay, 
and serum fibrin degradation products) in a large series 
of patients hospitalised with acute upper
gastrointestinal bleeding, and to relate these tests to 
outcome as well as to site and cause of bleeding; 
and (b) to measure these tests in a series of patients 
with oesophageal varices, and to relate them to presence 
or absence of bleeding, as well as to the Child's grade 
of severity.
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CHAPTER II 
METHODOLOGY
2.1.1 Collection of blood samples
Nine mis of blood was added to plastic tubes which 
contained 1 ml sodium citrate (3.2%) which had been 
precooled on melting ice. 2 ml of the sample was added 
to the FDP tubes at room temperature. Since there is a 
diurnal variation in plasminogen activator activity, the 
time was standardised (9-10 a.m.) The drip arm was
avoided to prevent dilution of blood. Minimal venous 
stasis was used to prevent release of tPA. Patients had 
to be resting and fasting (activity and food release 
tPA). The citrated samples were immediately refrigerated 
(4 C), centrifuged for 20 minutes (2000 r.p.m.) and the 
plasma underwent snap-freezing. FDP samples were kept on 
the bench to allow clot retraction. Therefore the tubes
were not shaken. They were centrifuged for 20 minutes at
c
2000 r.p.m. and then left at -45C to snap-freeze.
2.1.2 Plasma Plasminogen Activators - Fibrin Plate 
Lvsis Method
Plasminogen activators can be assayed by measuring 
the mean diameter of the area of lysis around a small 
volume of plasma euglobulin fraction placed on a plate of 
fibrin (which is contaminated with plasminogen) after 
incubation at 37 C. A standard preparation of fibrin 
avoids the variation in clot lysis time assays due to 
variable fibrinogen and plasminogen content of the test 
samples. A further advantage of fibrin plate assay is
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that plasma samples may be stored frozen (-20 C) for 
assay at a later date, then compared simultaneously, 
whereas clot lysis assays must be performed immediately. 
The method described is that of Kluft, Brakman and 
Veldhuyzen-Stolk (1976), modified by use of Kabi human 
fibrinogen and Owren's buffer. A device for accurate 
reading of the diameters of the areas of lysis has been 
described (Haverkate, 1972). The sensitivity of the 
plates is checked by testing standard preparations of 
streptokinase.
2.1.3 Reagents Required
a) Fibrinogen
One gram fibrinogen grade L from Kabi dissolved in
o
100 ml tris-Cl buffer. Stored frozen in -70 C freezer in 
10 ml aliquots.
b) Thrombin
Fibriquik thrombin reagent from General Diagnostics.
o
Dissolvedin 6 ml Tris-HCl buffer. Stored frozen in -70; C 
freezer in 3 ml aliquots.
c) Streptokinase
Streptokinase 100,000 units Topical Varidose from
Lederle. Dissolved in 50 ml Tris-HCl buffer, stored
o
frozen in-70|-C freezer in 0.5 ml aliquots.
d) Tris-HCl buffer
6.06 gm Trizma dissolved in 250 m 1 distilled water. 
400 ml distilled water added to 1.236 ml con. HC1. Add 
this to the Trizma solutions. Made up to one litre by 
adding 350 ml distilled water. Adjust pH to 7.4 by
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adding more HC1.
e) Owren's Buffer
m HC1 43ml
Na diethylbarbitone 11.756 gm 
NaCl 14.7 gm
o
Heated to 200 C and add water to 2 litres.
Adjust pH to 7.4 by adding more HC1.
f) Plastic Dishes
Flat plastic petri dishes (size approximately 100 x 
15 mm).
2.1.4 Method for Making Plates
To 90 ml Tris-HCl 10 mis (one aliquot) of fibrinogen 
was added and mixed in a measuring cylinder. 20 ml of 
mixture was applied to each plate. The plate was mixed 
and 0.5 ml thrombin was added. Plates were allowed to 
sit for at least 15 minutes, before moving. Streptokinase 
was diluted in 1 ml of tris buffer.
2.1.5 Sample Preparation
9 ml of distilled water was added to a conical test 
tube. 1 ml of sample was added and the tube put on ice.
pH was adjusted to 5.9 using 1% acetic acid and then put 
in a cold room for 15 minutes to allow the euglobulin 
fraction to precipitate out. Spinning for five minutes 
(2000 r.p.m.) in a cold centrifuge to form a button of 
euglobulin followed. The supernatant was decanted, the 
euglobulin residue was inverted and left to dry for about 
10 minutes.
Reconstitution took place in 1 ml Owren's buffer, 20
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ul of sample was added in triplicate and 20 ul of
o
streptokinase to the plate. Incubation at 37 C for 18 
hours followed.
The diameter of the lysis area was read in 2 
dimensions on special charts provided (Fig. 2.1). The 
diameters for the triplicate samples were averaged. The 
streptokinase control usually read 19 mm. (Fig. 2.2). If 
it did not then the value of the mean diameter was 
corrected using the following formula:-
Stand. streptokinase fl9mm,l x measured mean diameter 
measured streptokinase diameter 
The fibrin plate lysis area was obtained by the formula,
'T T r2
2.2 Serum Fibrin Degradation Products
(Tanned red cell Haemagglutination Inhibition 
Immunoassay; Merskey et al 1969; Walker et al 
1976)
2.2.1 Principle
Red blood cells are tanned then coated with human 
fibrinogen. These sensitised cells are sensitive
indicators of the presence of antibodies to 
fibrinogen-related antigen (FR-antigen), which cause 
agglutination. Prior incubation of antifibrinogen serum 
with a test serum sample containing a sufficient quantity 
of FR-antigen inhibits this haemagglutination. Serial 
dilutions of the test sample are incubated with 
antifibrinogen serum, prior to incubation with the 
fibrinogen-sensitised red cells. The lowest concentration
Figure 2. Chart illustrating method of measurement of 
F.P.L.A. in two planes; each point on the 
axes represents 2 mm
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Figure 2.2 A,B,C represents a patient sample in
triplicate in 3 areas: The measured mean
diameter is corrected using standard 
streptokinase (usually 19 mm) as the 
control (sk).
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of the test sample to cause complete inhibition o f  
haemagglutination is read and the concentration of the 
FR-antigen in the test sample is quantified by comparison 
with a serially-diluted fibrinogen standard.
Reagents These are provided in the Wellcome FDP kit
(Wellcome, Beckenham, Kent)
2.2.2 Sample Preparation
Two ml of venous blood was added to a special tube 
containing thrombin and enzyme inhibitor, incubated at 
room temperature, then centrifuged to obtain serum (i.e. 
removal of cross-reacting fibrinogen). Fibrinogen/fibrin 
related antigen was then measured by the tanned red cell 
haemagglutination immunoassay.
2.2.3 Reagents required
a) Citrate Buffer
Ten ml of five times concentrated buffer, pH 6.4 
containing when diluted 0.1 per cent sodium azide and 0.4 
per cent horse serum (pre-absorbed with sheep red 
cells).
The composition of the working-strength buffer was as 
follows:
Na HPO (anhydrous) 0.186g-
KHoP0 (anhydrous) 0.332gA 4
Trisodium citrate 0.735g
Citric acid, 0.5M sufficient to adjust pH
Sodium azide 0.05g
Horse serum (absorbed) 0.2ml
Distilled water to 50 ml
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b) Fibrinogen Sensitised Cells
The cells were gently centrifuged in a bench 
centrifuge and the supernatant removed with a pasteur 
pipette. 2.5 ml of working strength citrate buffer was 
added to the bottle. The cells were resuspended.
c) Anti-fibrinogen Serum
2.5 ml of working strength citrate buffer was added 
to a bottle of freeze-dried serum. The dissolved 
contents were mixed.
d) Fibrinogen Standard
0.5 ml of distilled water was accurately measured and 
added to the fibrinogen bottle. The contents were mixed 
to give a solution of 10 mg per ml fibrinogen.
e) Sheep Cells for Absorption
0.5 ml of suspended cells were added to a clean test 
tube. One tube was prepared for every sample of serum 
to be tested. Cells were washed in the tubes once with 
saline and the supernatant discarded leaving only freshly 
washed packed cells in each tube. Transfer 0.5 ml of 
clear serum to a tube cntaining the packed cells, mix and 
allow to stand at room temperature for 30 minutes. 
Centrifuge the tube and aspirate the clear serum.
f) Reading Plates and Pipettes
Microtiter apparatus (Flow Laboratories Ltd., Irvine, 
Scotland) was used. One microtiter 'V' plate contains 8 
rows of 12 wells, sufficient for assay of 7 samples in 
parallel with one fibrinogen standard titration. 0.025 
ml dropper pipettes are also supplied.
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2.2.4 Assay
To each microtiter plate was added (Fig 2.3):
1) Row 1
(Standard and reagent controls). Using 0.025 ml 
dropper 1 drop of citrate buffer was added to each of 
wells 2 to 10 and 2 drops in well 11.
2) Row 2 - 8
(7 test serum sample). 1 drop citrate buffer was 
placed in each of wells 2 to 9 and in well 12. 3) One 
drop of reconstituted fibrinogen standard was added to 
wells 1 and 2 of row 1.
4) One drop of undiluted serum (F.D.P. assay) was added 
to wells 1, 2 and 12 in the row appropriate to the sample 
under test. The dropper was rinsed in buffer between 
each sample.
5) A 0.025 ml micro-diluter loop was used to prepare 
serial dilutions from well 2 to well 9 in each row, 
discarding a loopful of the final dilution after mixing 
in well 9.
6) Using a clean dropper, one drop of reconstituted 
antiserum was added to wells 1 to 10 in row 1 and to 
wells 1 to 9 of all other rows.
7) The contents of all wells was mixed by gently shaking 
the plate. The plate was covered and left on the bench 
for one hour.
8) Using a clean dropper one drop of freshly resuspended 
fibrinogen-sensitised cells was added to wells 1 to 11 of 
row 1 and wells 1 to 9 and well 12 in all other rows.
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Figure 2.3 F.D.P. Kit: Endpoint in Row 1 = Well 4
Sensitivity of assay = 1.25 ug/ml 
Endpoint in Row 6 = Well 3,
Dilution Factor = 4
Thus concentration of F.D.P. in serum 
tested in Row 6 is 4x1.25 = 5 ug/ml.
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9) The contents of the wells were mixed again. The 
plate was covered and left on a bench (away from direct 
sunlight or vibration) for a minimum of two hours after 
which time results were read by inspection of the 
sedimented patterns in individual wells. The completed 
plate contained standard and samples as follows:
2.2.5 Calculation of Results
Row 1 To determine sensitivity of assay (fibrinogen 
concentration at end point).
1 2 3 4  5 6 7 8 9
10 5 2.5 1.25 0.63 0.32 0.16 0.08 0.04
Row 2 to 8 The end point of each sample was read. The 
dilution factor at endpoint was multiplied 
by sensitivity of assay to give 
concentration of serum F.D.P. 
1 2 3 4 5 6 7 8 9  
1 2 4 8 16 32 64 128 256
e.g. Endpoint in Row 1 = Well 4 sensitivity of assay =
1.25 ug/ml.
Endpoint on Row 2 = Well 3 Dilution Factor = 4 
Thus concentration of F.D.P. in serum tested in Row 2 = 4  
x 1.25 = 5 ug/ml
2.3 Rapid Latex-Screening Test (Thrombo Wellcotest)
The test is intended for the rapid semi-quantitative 
testing of human serum for the presence of 
fibrin/fibrinogen degradation products (F.D.P.).
It is a simple and rapid test which allows the 
routine investigation of all patients at special risk.
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The test is designed as a slide agglutination method in 
which one drop of sample and one drop of latex suspension 
are mixed for a period of two minutes by gentle rocking. 
An agglutinated pattern at the end of the test period 
indicates the presence of at least 2 ug per ml F.D.P. in 
the sample under test. The test was performed 
retrospectively in this study to determine its utility in 
the prognosis of acute upper gastrointestinal bleeding.
2.3.1 Principle of the Test
Antisera are raised to highly purified preparations 
of human fibrinogen fragments D and E. After solid-phase 
absorption to remove antibodies to all other serum 
proteins, the specific antibody globulins are extracted 
and used to coat by absorption a suspension of latex 
particles in glycine saline buffer. The sensitivity
of the latex reagent is adjusted so that in the presence 
of F.D.P. concentrations of 2 ug (fibrinogen equivalent) 
per ml or greater, the latex particles clump together 
giving macroscopic agglutination.
2.3.2 Reagents Required (Supplied in Thrombo-Wellcotest, 
Wellcome, Beckenham, Kent)
a) Latex Suspension
3 ml of a 0.75 per cent suspension of polystyrene 
latex particles coated with sheep anti-F.D.P. globulin 
glycine saline buffer containing 0.1 per cent sodium 
azide and 0.01 per cent thiomersal.
b) Positive Control Serum
1 ml of human serum diluted in glycine saline buffer
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containing 0.1 per cent sodium azide to give an F.D.P. 
concentration of 5-10 ug per ml.
c) Negative Control Serum
1 ml of human serum diluted in glycine saline buffer 
containing 0.1 per cent sodium azide to give an F.D.P. 
concentration less than 2 ug per ml.
d) Sample Collection Tubes
20 glass tubes containing soya bean trypsin inhibitor 
(approximately 3600 NF units per tube) and bovine 
thrombin (20 NH units per tube) for the collection of two 
ml whole blood.
e) Glycine Saline Buffer
Two bottles each containing 25 ml of pH 8.2 buffer 
having the following composition:
Glycine 7.507 gram
NaCl 8.5 gram
NaOH M/5 Sufficient to adjust pH
Sodium azide 1.0 gram
Distilled water to 1.0 litre
f) Disposable pipettes and mixing rods. Rubber bulb.
g) Test Slide:
One slide with 6 rings to test 3 samples or 2 samples 
with control.
2.3.3 Handling of Reagents
It is desirable to bring all reagents approximately 
to room temperature before use. The latex suspension 
was mixed thoroughly by rapidly inverting the bottle two 
or three times immediately prior to performing the test.
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The control sera were provided diluted ready for use. No
further preparation was necessary.
2.3.4 Specimen Collection
This was as for the quantitative FDP method.
2.3.5 Procedures for Assay of F.D.P.
(a) Using the graduated dropper provided with the 
bottle of buffer, 0.75 ml of glycine saline 
buffer was placed in a test tube.
(b) Using one of the disposable droppers with the 
bulb provided, five drops of the serum sample 
were added to the test tube.
(c) The contents of each test tube which now 
contain approximately 1.5 dilutions of serum 
were mixed. One drop from the test tube was 
transferred to the reaction slide.
(d) The latex suspension was mixed by rapidly inverting 
the bottle two or three times and then one drop of 
the suspension was added to each position on the 
slide.
(e) The slide was gently rocked to and fro for exactly 
two minutes while looking for macroscopic 
agglutination. The patterns obtained are
clear cut and can easily be recognised under any 
normal conditions of lighting. The presence 
or absence of agglutination was determined 
immediately after rocking the slide for two 
minutes. If the reaction was allowed to continue 
for longer, false results might occur due to drying
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out of the mixture on the slide.
2.3.6 Reading of Results
The kit is adjusted to a sensitivity of 2 ug per ml. 
An agglutinated pattern in either position on the slide 
indicates the presence of F.D.P. at a final concentration 
of greater than 2 ug per ml in the serum dilution. A 
positive result in position 1 indicated that F.D.P. were 
present in the original serum at a concentration in 
excess of 10 ug. per ml. (Fig. 2.4).
2.4 Measurement of Crosslinked Fibrin Degradation 
Products with an Immunoassay using Monoclonal 
Antibodies against D-dimer 
The serum F.D.P. assay described above is unable to 
distinguish between degradation products of fibrinogen 
and fibrin. It also shows high levels in normal serum 
due to generation of FDP's during clotting 
(Nieuwenhuizen, 1987).
The Dimertest (AGEN, Parsippany, New Jersey), 
provides a simple and precise enzyme immunoassay for 
crosslinked fibrin degradation products containing the 
D-dimer (Elms et al 1983).
2.4.1 Reagents
1 - Microtiter plate of 96 wells coated with mouse
monoclonal anti D-Dimer antibody and buffer 
containing 0.1% sodium azide as preservative.
2 - Vial Tag antibody, mouse monoclonal anti-F.D.P.
peroxidase conjugate.
3 - D-dimer standard containing purified human D-dimer,
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Figure 2.4 Rapid latex screening test (a) control
positive (b) control negative (c) patient 
positive (d) patient negative
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with preservative (lyophilized).
4 - Tween 20, 40 V/V 5 ml (green cap)
5 - Vial ABTS substrate, (2,2-Azinobis (3-Ethyl-
benzthiazoline solfonic acid) in citrate buffer 
10 ml .
6 - Hydrogen peroxide, 30% V/V 1 ml.
7 - Stopping reagent 5 ml (red cap).
8 - Vial diluent 3.5 ml.
9 - Bottle phosphate buffer salts.
Methods for preparation of the above reagents are 
described by Elms et al (1983).
2.4.2 Specimen Collection
Serum values are generally lower than plasma values 
(Whitaker 1984). Plasma is preferred, and was used in
the present study (prepared from citrated blood).
o
Frozen plasma samples were thawed at 37: c and mixed 
well and centrifuged before assay.
2.4.3 Assay Preparation 
Buffer Reagent
The contents of the phosphate buffer salts bottle and 
the contents of the Tween 20 vials (5 ml) were mixed in a 
beaker containing 1 litre distilled water. This 
produces a final Tween concentration of 0.2% V/V.
D-dimer standard preparation
(a) The vial of standard was reconstituted with 
diluent according to the instructions on the vial to give 
a concentration of 5000 ng/ml.
(b) The standard was left for 10 minutes, then mixed
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gently until complete solution was obtained.
(c) A range of serial dilutions of the reconstituted 
standard was prepared for standard curve construction 
according to the following protocol:
Reconstituted standard Dilutent D-Dimer
Concentration na/ml
A 1.0 ml 5000
B 0.2 ml of A 0.2 ml 2500
C 0.2 ml of B 0.2 ml 1250
D 0.2 ml of C 0.2 ml 625
E 0.2 ml of D 0.2 ml 312
F 0.2 ml of E 0.2 ml 156
G 0.2 ml of F 0.2 ml 78
H 0.2 ml 0
A standard curve was included on each occasion the assay 
was run.
Washing the coupled plates
(a) Just before use, the microtiter plate was 
opened.
(b) The plate was inverted and the plate contents 
shaked out. The plate was washed with buffer reagent, 
left 2 minutes, then emptied. The plate was blotted by 
inverting on absorbent material to remove excess liquid.
2.4.4 Assay Procedure
The order of steps was as follows -
(1) Addition of standards and unknown samples.
(a) Addition of 100 ul of buffer reagent to each well.
(b) Addition of 25 ul of standards and unknown plasmas.
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Determinations were done in duplicate. The assay 
range was 20-5000 ng/ml. Samples containing higher 
levels of D-dimer were diluted in buffer reagent 
before assay.
(c) Samples were mixed gently and incubate for 1 hour 
at room temperature.
(2) Tag antibody-enzyme conjugate was added after 
reconstitution of the Tag antibody by adding 5.5 ml 
buffer reagent.
(a) Again, the plate was washed 3 times with buffer 
reagent, as described previously.
(b) 50 ul reconstituted Tag antibody was added to each 
well and incubated for one hour at room 
temperature. Again the plate was washed three 
times as described previously.
(3) Colour Reaction.
(a) 10 ul of hydrogen peroxide was added to the 
ABTS substrate vial and mixed well.
(b) Pipette 100 ml of this activated substrate was 
pipetted into each well.
(c) The plate was incubated at room temperature for 20 
minutes to allow colour development.
(d) 50 ul stopping reagent was pipetted into each well 
to stop the reaction.
(e) The absorbance of each well was read at 405-450 mm 
(optimum 420 mm).
2.4.5 Calculation of Results
Results were plotted using log-linear or log-log data
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reduction.
(a) Optical density (O.D.) was plotted against D-dimer 
concentration. The best curve was drawn through 
the mean of the duplicate points, rejecting grossly 
aberrant readings. A typical curve was shown in 
Fig 2.5.
(b) The mean O.D. for each unknown was calculated and 
read off the D-dimer concentration from the 
standard curve.
(c) Samples that read greater than 5000 ng/ml were 
diluted in buffer reagent for re-estimation.
2.5 Statistical Methods
The statistical analysis used both parametric and 
non-parametric tests, depending on whether or not it was 
appropriate to assume that the data were normally 
distributed. In the former case both paired and 
two-sample t-tests were used. In the latter case paired 
analysis used the Wilcoxon signed rank test and unpaired 
analyses were based on the Wilcoxon Rank sum test. If 
three or more groups were being compared simultaneously, 
the analysis used the Kruskal-Wallis test followed up by 
ranked Wilcoxon rank sum tests. A Fisher's test was used 
for discrete variables with small numbers in each cell.
A p-value of less than 0.05 was taken as being 
statistically significant. To determine the independent 
prediction of outcome by fibrinolytic assays, 
multivariate analysis was performed using logistic 
regression analysis on a mainframe computer using the
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BMDP statistical package (Dr. G.D. Murray).
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CHAPTER III 
VARIABILITY OF MEASUREMENTS
3.1 Introduction
Before proceeding to investigate the role of the 
fibrinolytic system in the pathogenesis of acute upper 
gastrointestinal bleeding, estimation of the 
reproducibility of the measurements in the hands of the 
author was required. In addition, the variability of 
fibrinolytic activity in relation to sampling time was 
assessed, to confirm the recognised diurnal variation in 
plasminogen activator levels (Lowe and Prentice 1980).
3.2 Coefficient of variation of F.D.P. estimation
3.2.1 Method and Subjects
The level of the F.D.P. was measured in 2 volunteers 
for validation of the accuracy of the technique.
Estimations of the level were made 10 times in each 
volunteer.
Two healthy male volunteers aged 35 and 45 years who 
work in the Department of Surgery were studied.
Antecubital venous blood samples were obtained by 
clean venepuncture with minimal venous occlusion, after 
proper sterilization of the skin, with plastic disposable 
syringe. Neither subject was fasted or had normal 
activity restricted in any way. Samples were taken at 9 
a.m.
Twenty mis of blood were taken from each volunteer 
and evenly distributed between 10 test tubes i.e. 2 mis 
in each. Each of the 10 test tubes contained soya bean
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trypsin inhibitor (approximately 3600 UF units per tube) 
and bovine thrombin (20 NIH units per tube). The tubes 
were incubated at room temperature until separation of 
the serum. As soon as possible, the serum was removed 
after centrifugation at 2000 r.p.m. for 10 minutes. All 
serum samples were stored at -45 C. F.D.P. levels were 
measured as mentioned previously (Chapter II).
3.2.2 Results
The results of the F.D.P. levels of the two 
volunteers are shown in Table 3.1
There was no variation of F.D.P. measurement noted in 
the ten samples in the second volunteer, while analysis 
of the samples from the first subject had a coefficient 
of variation of 10.9%. This indicates a satisfactory 
analytical technique, with the mean level of the 
coefficient of variation being 5.45%.
3.3 Coefficient of variation of fibrin plate lysis 
area (FPLA)
For validation of the accuracy of the technique used, 
the F.P.L.A. levels were measured 10 times in one healthy 
male volunteer aged 40 years. Antecubital venous blood 
samples were obtained by clean venepuncture with minimal 
venous occlusion. Fifty mis of blood were taken. Four 
and a half mis whole blood was added to each of 10 
numbered tubes each of which contained 0.5 ml sodium 
citrate.
The tubes were put on melting ice until separation of 
the plasma. Plasma was removed by centrifugation at 2000
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Table 3.1 F.D.P. levels for both volunteers. 
(Taken on 10 occasions)
Volunteer 1 Volunteer 2
No. (pg/ml) (pg/ml)
1 3.7 2.5
2 3.75 2.5
3 3.75 2.5
4 2.5 2.5
5 3.75 2.5
6 3.75 2.5
7 3.75 2.5
8 3.75 2.5
9 3.75 2.5
10 3.75 2.5
- 112 -
a
r.p.m. for 10 minutes at 4. C temperature. All plasma 
samples were stored at -45: c.
Analysis was by the method discussed in Chapter 2.
The results are shown in Table 3.2.
3.3.1 Results (Table 3.2)
The variation of the lysis area in the 10 samples was 
within an acceptable range and indicated that the proper 
technique had been employed. The mean coefficient of 
variation in this experiment was 6.48%.
The variation in lysis area therefore was within 
acceptable limits and indicates a satisfactory analytical 
technique.
3.4 Significance and assessment of diurnal variation 
in measurement of fibrinolytic activity 
Diurnal variation in fibrinolytic activity of blood 
is well recognised, with a rise in activity during the 
morning (Fearnley et al 1957; Kanaik et al 1957, 1958;
Swinska-Kotschy and Glogowska 1958; Billimoria et al 
1959; Buckell and Elliot 1959; Kowarzyk et al 1959; 
Fearnley 1960; Hajjar et al 1961; Lackner and 
Sougin-Mibashan 1964; Menon 1966a; Moser and Hajjar 
1966). Most of these authors used the F.P.L.A to
assess the variations observed in normal subjects' 
fibrinolytic activity, and in most cases healthy 
volunteers were used. It has recently been suggested that 
diurnal variation results from diurnal variations in 
plasminogen activator inhibitor (Kruithoff, 1988). 
Variations may also occur as a reaction to stress. They
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have been noted to vary both from person to person and in 
the same individual from day to day (Kowarzyk et al 
1960). Fibrinolytic activity is elevated as a result of 
exercise (Menon 1966b; Menon et al 1967), anxiety 
(Macfarlane and Biggs 1944; Latner 1947; Truelove 1951) 
and subcutaneous injection of adrenalin (Truelove 1953).
A diurnal rhythm in the rate of excretion of 
17-ketosteroids was first described by Pincus (1943) and 
in 17 hydroxysteroids by Bliss et al (1953).
The peak concentrations of both groups of steroids 
arise between 6 a.m. and 8 a.m. after which the level 
gradually falls to a nadir at 4 p.m. remaining at this 
level until midnight (Wajchenberg et al 1964). These 
variations are thought to reflect changes in the rate of 
corticotrophin secretion by the pituitary glands (Perkoff 
et al 1959). The variations may be related to but are 
more consistent than those of fibrinolytic activity 
(Chakrabarti et al 1964). Significantly higher plasma 
levels of free 17-OHCS are found in otherwise healthy 
individuals with anxiety than in tranquil people (Hill et 
al 1956; Persky 1957), the 8 a.m. level being almost 
double the normal (Persky et al 1956). Corticosteroids 
will reduce fibrinolytic activity when this is of a 
pathological degree e.g. in hepatic cirrhosis (Kwaan et 
al 1956).
Menon and colleagues (1967) have measured 
fibrinolytic activity as assessed by euglobulin lysis 
times and found a loose inverse relationship to plasma
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II-hydroxysteroid level. Their subjects had a 
significant decrease in euglobulin lysis times between 9 
a.m. and 4 p.m. They included 5 bedridden ill patients 
and found that the normal rhythm in fibrinolytic activity 
was significantly reduced in these patients.
3.5 Diurnal variation in fibrinolytic activity as 
assessed by Fibrin Plate Lysis Area
3.5.1 Method and Subjects
To check normal levels of F.P.L.A 10 normal male
volunteers working in the Royal Infirmary Department of
Surgery (age range 25-45 years, mean age 30 years) were
examined. None of them were subjected to fasting or had
their activity restricted during the study. Venous
samples were taken from the antecubital fossa as
previously discussed. Three venous samples were taken
from each volunteer at 09.00, 12.00 and 17.00 hours. It
was assumed that such times would reveal a diurnal
rhythm. Four and a half mis of blood was added to test
tubes containing 0.5 ml. sodium citrate and this was kept
on melting ice until separation of the plasma occurred.
The plasma was removed after centrifugation at 2000
o
r.p.m. for 10 minutes at 4 ;C. All plasma samples were
o
stored at -45 ;C. The analytical methods were as 
previously discussed.
3.5.2 Results
The results of the F.P.L.A in the blood taken from 
the 10 volunteers at 09.00, 12.00 and 17.00 are shown in 
Table 3.3 and Figure 3.1.
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Table 3.3 Ten volunteers 
lysis area at 
each patients.
measurement 
9.00, 12.00,
fibrine plate 
17.00 hours f<
No. 9 a.m. 12 noon 5 p.m
(mm2)
2
(mmr) (mm2)
1 85.1 107.6 132
2 45.3 96.1 85.7
3 80.4 90.9 96.2
4 96.2 145 119
5 91 119 102
6 95 151.6 131.8
7 50.24 50.24 55
8 60 100.6 92.7
9 43.3 110.3 96.2
10 50.4 90.13 80.7
Mean 70.6 106.2 99.1
SD 20.9 28.9 23.8
Median 60 100.6 96.2
Sample 
Range 43. 3-96 50-151 55-132
0
0
2
117 -
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The normal range of F.P.L.A at 09.00 ranged from 43.3 
mm2 to 95.1 mm2.
The mean was 70 mm2 in this study. Nine volunteers 
showed an increase in fibrin plate area from 09.00 to 
12.00, the other one volunteer did not. Between 12.00 to 
17.00 F.P.L.A in most of the volunteers decreased. In 
only 3 volunteers did the FPLA continue to increase 
between 12 and 5 p.m.
3.5.3 Statistics
Comparing groups on all data using the Friedman 
non-parametric test to see if there were group 
differences gave P < 0.001. As there was a difference, 
the Wilcoxon Signed Ranks test was used to compare 
pairs.
9 a.m. to 12 p.m. P = 0.009 Significant
9 a.m. to 5 p.m. P =  0.006 Significant
12 p.m. to 5 p.m. P = 0126
3.5.4 Conclusions
1 - Fibrinolysis increases between 9 a.m. and 12 noon,
and starts to decrease after 12 noon.
2 - In the morning there is an increase in blood
fibrinolytic activity, followed by a more gradual 
decrease between 12 noon and 5 p.m. These findings 
are consistent with the literature reviewed above 
above.
3 - In some volunteers (2 out of 10) fibrinolysis
increased continuously during the day from 09.00 to 
17.00.
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3.6 Diurnal variation in fibrinolytic activity as 
assessed bv serum F.D.P. level
3.6.1 Methods and Volunteers
To establish the normal level of F.D.P. and to 
examine diurnal variation 10 volunteers (age range 25-45 
years, mean age 30 years) were examined. All of them 
were men who worked in the Royal Infirmary Department of 
Surgery, Glasgow. No subject was fasted or had activity 
restricted during study.
Three venous samples taken from the antecubital fossa 
from each volunteer at 09.00, 12.00 and 17.00 hours.
Samples were assayed by the method discussed in Chapter
II. Two mis of blood was added to test tubes as 
discussed earlier. Each test tube contained soya bean 
trypsin inhibitor (approximately 3600 UF units per tube) 
and bovine thrombin (20 NIH units per tube). Each tube 
was reput at room temperature until separation of the 
serum occurred. The serum was removed after
centrifugation at 2000 r.p.m. for 10 minutes. All serum
0
samples were then stored at -45 C.
Analytical method was as previously discussed.
3.6.2 Results
The results of the F.D.P. levels in the 10 volunteers 
(ages 30-40 years) at 09.00, 12.00 and 17.00 hours are 
shown in Table 3.4.
The normal variation of F.D.P. ranged from 1.25 ugm - 
5 ugm in this study.
However no diurnal variation was observed in the
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Table 3.4 F.D.P. level (ug/ml) in serum from 10
volunteers at 09.00, 12.00 and 17.00 hours.
Number 09.00 12.00 noon 17.00
(pg/ml) (fjg/ml) (jjig/ml)
1 5 5 5
2 2.5 2.5 2.5
3 3.75 3.75 3.75
4 2.5 2.5 2.5
5 3.75 3.75 3.75
6 1.25 1.25 1.25
7 5 5 5
8 2.5 2.5 2.5
9 5 5 5
10 2.5 2.5 2.5
Mean 3.4 3.4 3.4
Median 2.5 2.5 2.5
SD 1.5 1.5 1.5
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level of F.D.P. as shown in these volunteers.
3.6.3 Statistics
There was no statistically significant difference 
between the 3 groups indicating no diurnal variation in 
F.D.P. level.
3.7 Conclusions
1 - The coefficient of variation of repeated F.D.P.
estimations in 2 volunteers was satisfactory, with 
the level of the mean coefficient of variation 
being = 5.45%.
2 - The coefficient of variation of the F.P.L.A
technique when measured 10 times in one 
volunteer was within the acceptable range. The 
mean coefficient of variation in this experiment 
was 6.48%.
3 - The normal level of F.P.L.A in this study (no
subject was fasted or had their activity restricted) 
at 9.00 in the morning was 70 mm2 mean (range 43 
mm2 - 96 mm2).
4 - A diurnal variation in fibrinolytic activity
assessed by FPLA was observed. The level increased 
in the morning and decreased after 12 p.m. Two out 
of 10 volunteers had increased fibrinolysis until 5 
p.m.
5 - The level of F.D.P. in the serum was 3.4 ug/ml mean
(range 1.25 ug/ml - 5 ug/ml).
6 - There was no diurnal variation in fibrinolytic
activity as assessed by serum F.D.P. This makes it
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potentially more useful as a prognostic test in 
acute bleeding, compared to the F.P.L.A.
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CHAPTER IV 
UPPER GASTROINTESTINAL BLEEDING
As the prognostic significance of enhanced 
fibrinolysis on severity and recurrence of UGIT bleeding 
has not been clearly identified in human beings, it was 
decided to study tests of the fibrinolytic activity among 
a group of patients with haematemesis or melaena admitted 
to Glasgow Royal Infirmary.
4.1 The Selection Criteria
The selection criteria for inclusion of the patients 
in the study were as follows
a) Patients admitted with haematemesis or 
melaena or both regardless of presumptive 
clinical diagnosis.
b) Patients with blood dyscrasias, or on anti­
coagulant, thrombolytic or antifibrinolytic 
therapy were excluded. Any patient admitted 
with a history of bleeding more than 24 hours 
before admission were also excluded.
4.2 Patient Recruitment
In Glasgow Royal Infirmary, patients with UGIT 
haemorrhage are admitted under the care of the 
physicians. Patients are admitted to a medical 
receiving unit where they are stabilised and at the post 
receiving ward round the next day, the consultant decides 
if he wishes endoscopy to be carried out. The patient is 
then referred to the duty endoscopist. Seriously ill 
patients who require immediate laparotomy obviously
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bypass this system and because of the necessity to 
standardise the time at which blood samples are taken it 
was not possible to include several patients with active, 
profuse bleeding admitted and operated upon within a few 
hours. It was not necessary for the validity of this 
study to include all patients with UGIT bleeding and no 
attempt has been made to recruit a consecutive series.
At 09.00 hours ward visits were made for collection 
of basic data from patients with acute UGIT bleeding for 
whom endoscopy was requested, plus blood samples. 
Sampling was left until all patients had been seen, then 
all samples were taken together (within 10 minutes, hence 
maximum of 3 at one time). Venous samples of at least 13 
mis in a 20 ml syringe were collected as detailed in 
section 2.1.
4.3 Patient details and information
In this prospective study 122 patients with upper GIT 
bleeding were included. All the patients were admitted 
to the Royal Infirmary, Glasgow during the period April 
1986 - April 1988. All had been bleeding from the UGIT. 
They included 73 (60%) men and 49 (40%) women.
For every patient various data were recorded as 
follows:
4.3.1 History
a) Personal Data
1 - Name, study number, address, telephone number.
2 — General Practitioner's (G.P.) name and
address.
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3 - Hospital number, date of birth and sex.
4 - Ward number and name of consultant.
5 - Date of onset of bleeding, date of
admission and date of the blood sample and
follow up.
b) Haemodynamic State
1 - Pulse rate/minute
2 - Blood pressure systolic/diastolic
c) Intravenous Infusion
1 - Units of blood transfused
2 - Units of plasma/colloid
3 - Units of crystalloid
4.3.2 Clinical Data
a) All patients had either
1 - Haematemesis
2 - Haematemesis and melaena
3 - Melaena
b) History of drug-induced bleeding
1 - Non steroid anti-inflammatory drugs (NSAID)
2 - Steroids
c) Alcohol Ingestion
1 - Non drinker
2 - Previous drinker
3 - Current social drinker (less than 10 units/week)
4 - Heavy drinker
d) Smoking: number smoked per day
e) Weight (kg), height (cm) and % ideal body weight
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4.3.3 Routine Laboratory Data
a) Haemoglobin
b) Serum bilirubin
c) Serum creatinine
4.3.4 Endoscopic Findings
a) Anatomical diagnosis and site of bleeding
1 - Oesophagus
2 - Stomach
3 - Duodenum
4 - Stoma
b) Pathological Diagnosis 
1 - Oesophagus
i Oesophagitis
ii Hiatus hernia
iii Mallary Weiss syndrome
iv Varices
V Carcinoma
vi Peptic ulcer (benign ulcer)
- Stomach
i Gastritis
ii Carcinoma
iii Gastric ulcer
iv Gastric erosion
3 - Duodenum
i Duodenitis 
ii Duodenal ulcer
c) Diagnosis of Stigmata 
1 - Visible vessel
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2 - Active bleeding
3 - Slough
4 - Fresh clot
5 - None of above
4.3.5 Laboratory Work
a - Measurement of fibrin plate lysis area (F.P.L.A.) of 
euglobulin plasma fraction, 
b - Measurement of serum fibrin/fibrinogen degradation 
products (F.D.P.). 
c - D-Dimer test for plasma cross-linked F.D.P. 
d - Latex test for serum F.D.P.
4.3.6 Treatment
a - Medical treatment (drug therapy)
1 - Antacid
2 - Cimetidine or Ranitidine
3 - Prostaglandine E2
4 - Somatostatin
5 - Tranexamic Acid 
b - Laser therapy
c - Surgical treatment
1 - Undersewing of vessel
2 - Undersewing of vessel plus
i Vagatomy and drainage 
ii Partial gastrectomy 
iii Total gastrectomy 
iv Injection of varices 
v Transection of oesophagus 
vi Laparotomy alone
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4.3.7 Outcome
All patients were followed from the evaluation until 
discharge or death. In hospital survival and date of 
discharge were recorded, also date of death and post 
mortem result.
Further bleeding (continuous or re-bleeding) was 
recorded as well as surgery, laser treatment or blood 
transfusion.
The definition of recurrent or continuous bleeding 
was made on clinical grounds. Where the patient had a 
period of haemodynamic stability and endoscopy showed no 
active bleeding and the patient subsequently developed 
further signs of hypotension or tachycardia suggestive of 
further blood loss or a further haematemesis revealed 
fresh blood, recurrent bleeding was recorded. If the 
patient's haemodynamic state continued to require the use 
of blood or plasma expanders and continued fresh bleeding 
was found at endoscopy, the patient was judged to have 
continuous bleeding.
4.4 Results
4.4.1 Clinical Results
The ages of the 122 patients ranged from 19 years to 
80 years with a mean of 54 and median of 56 years.
This number comprised 73 (60%) men and 49 (40%)
women. The age and sex distribution is shown in fig. 
4.1.
Their haematemesis and/or melaena was of variable 
severity. Severity was judged by requirement of blood
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Figure 4.1 Sex and age distribution of UGIT bleeding 
patients admitted to study.
- 130 -
transfusion. Fifty-six (46%) out of the total 122 
patients needed blood transfusion. The total
requirements were 302 units of blood, a mean of 5 units 
per transfused patient. However, the severity of blood 
loss was very variable among those individuals who 
required blood transfusion i.e. the minimum requirement 
was 1 unit and the maximum was 29 units.
Twenty-four (20%) patients had plasma transfusion. In 
total 172 units plasma were required, within the range 1 
to 40 units. The sample median was 6 units.
64 (52%) patients from the total of 122 required in 
total 1691 units of crystalloid fluid for intravenous 
infusion, within the range 1 unit to 150 units. The
sample mean was 26 units.
Sixty-six (54%) patients from the total had 
haematemesis only, 52 (43%) had both haematemesis and 
melaena, and 4 (3%) had melaena only. 45 (37%) had
previously had a peptic ulcer, and 54 (44%) had history
of previous UGIT bleeding.
Ten (8%) patients did not consume alcohol, 30 (25%) 
were previous drinkers and had not consumed any within 
the previous year, 54 (44%) were current social drinkers 
drinking less than 10 units/week and 27 (22%) were
current heavy drinkers. One patient was unsure of his 
category (Fig. 4.2).
Seventy—three (60%) out of the total 122 patients 
smoked. The total smoking habit was 1243 cigarettes per 
day. The mean was 17 cigarettes per day per smoking
N
um
be
r 
of 
pa
ti
en
ts
- 131 -
60 n
50-
40-
30-
20
Number
Not Previous S ocia l Heavy 
Drinker
Figure 4.2 Distribution of drinking habits of UGIT 
bleeding patients according to 
classification described on p 130.
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patient (range 3 to 60 cigarettes per day) and median was 
12 cigarettes per day.
The haemoglobin level of patients at admission was 
important because it is one of the risk factors in upper 
GIT bleeding (Northfield, 1971; MacLeod et al, 1982). In 
some patients, especially those with a bleeding peptic 
ulcer, the lower the haemoglobin level at admittance the 
greater the mortality rate (Himal et al 1974). Their 
haemoglobin levels ranged from 5.2 g/dl to 12 g/dl with a 
mean of 11.96 g/dl and median of 12 g/dl.
The ranges of serum bilirubin in patients varied from 
2 umol/1 to 150 umol/1 with sample mean of 22 umol/1 nd 
median of 10 umol/1.
The serum creatinine level in patients ranged from 20 
umol/1 to 360 umol/1 with a mean of 73 and median of 70 
umol/1.
4.4.2 Endoscopic findings
Twenty (16%) patients out of a total of 122 patients 
were undiagnosed after endoscopy, and 102 (84%)
diagnosed.
4.4.3 Anatomical findings (Fig. 4.3)
a) Oesophagus -34 (33%) patients (of these 34 patients 
there were 24 (71%) men and 10 (29%) women.
b) Stomach - 34 (33%) patients (of these 34 patients 
21 (62%) were men and 13 (38%) were women).
c) Duodenum - 32 (31%) patients (of these 32 patients 
the sex prevalence indicated 18 (56%) men and 14 
(44%) women).
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Figure 4.3 Anatomical site of bleeding (oesophagus, 
stomach, duodenum) and corresponding sex 
incidence.
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d) Stoma 2 (2%) patients, one man and one woman.
4.4.4 Pathological findings (Figure 4.4)
Pathological investigation indicated a number of 
causes of bleeding from the oesophagus, stomach and 
duodenum.
Oesophagus
1 - Oesophagitis This was noted in 3 cases, 2 male (67%) 
and 1 female (33%). These 3 cases were 2% from the 122 
patients who had been bleeding from upper GIT and 3% of 
102 diagnosed patients. Of the patients suffering from 
oesophageal bleeding, oesophagitis was the cause in 9% of 
the cases.
2 - Mallorv Weiss Syndrome
12 patients were diagnosed as bleeding from Mallory 
Weiss syndrome. Nine (75%) of these were male and 3 
(25%) were female. This represented 10% of the total 
study group.
They also represented 35% of the 34 patients 
suffering from oesophageal bleeding.
3 - Oesophageal Varices
15 patients were bleeding from oesophageal varices of 
which 12 (80%) were male and 3 (20%) were female. These 
patients represented 12% of those with upper GIT 
bleeding, 15% of those diagnosed, and 44% of oesophageal 
bleeding.
4 - Four patients (2 male, 2 female) were found to have 
benign oesophageal ulcer in this survey. Three per cent 
of UGIT bleeding was caused by this condition and 4% of
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Figure 4.4 Pathological diagnosis of acute upper
gastrointestinal bleeding. Total number 
and corresponding sex incidence.
O: Oesophagitis; M.W.; Mallory Weiss
Syndrome; OV: Oesophageal Varices;
OU: Benign oesophageal ulcer;
GU: Gastric ulcer; G: Gastritis;
Ca: Gastric carcinoma; G.E. Gastric
erosion; D: Duodenitis; D.U.: Duodenal
ulcer.
- 136 -
diagnosed cases. Of these with oesophageal bleeding the 
4 patients represented 12%.
Stomach
34 patients from the original 122 monitored were 
bleeding from the stomach. The sex incidence was 21 
(62%) males and 13 (36%) females. The causes were as 
follows:
1 - Gastritis
This was noted as the sole cause in 12 patients, 8 
(67%) male and 4 (33%) female. Of these patients
experiencing upper GIT bleeding 10% of the cases were 
caused by gastritis and of the diagnosed cases this 
number represented 12%. This condition was the cause of 
35% of cases of bleeding from the stomach.
2 - Gastric Erosions
This condition was diagnosed in 5 patients, 4 (80%) 
male and 1 (20%) female.
This represented 4% of the patients who had been 
bleeding from UGIT. Of the 34 cases who were bleeding 
from the stomach these 5 patients represented 15%.
3 - Gastric Ulcer
Gastric ulcer was found in 15 patients of whom 8 
(53%) were male and 7 (47%) female. This represented 
12% of the total number of cases of UGIT bleeding, and 
15% of those diagnosed. From the 34 cases of gastric 
bleeding this was 44%.
4 " Carcinoma of Stomach
Two patients were found to have a malignant ulcer#
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one male and one female.
Duodenum
1 - Duodenal Ulcer
Twenty nine patients had a duodenal ulcer, 15 (52%)
male and 14 (48%) female. This appeared to be the cause 
of 24% of all cases of upper GIT bleeding and 28% of the 
102 diagnosed cases of upper GIT bleeding. Of the 32 
suffering duodenal bleeding this was the cause of 91% of 
the cases.
2 - Duodenitis
Three people had the above condition, all patients 
were male. This accounted for 2.5% of people suffering 
upper GIT bleeding and 3% of diagnosed bleeding. 
Duodenitis represented the remaining 9% of cases of 
duodenal bleeding.
Stomal Ulcer
Two patients were diagnosed as bleeding from a stomal 
ulcer, one male and one female. Of the 122 cases of 
upper GIT bleeding this was less than 2%.
4.4.5 Outcome
The 15 patients who had bleeding oesophageal varices 
were all given sclerotherapy by injection using rigid 
endoscopy. Five of them died, thus the mortality rate in 
bleeding oesophageal varices was 33%.
In gastric bleeding, of the 34 patients one was given 
laser treatment, 28 were given medical treatment, and 5 
patients required surgery. Three of these died.
Three patients suffering from a gastric ulcer were
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treated by surgery, all survived. One patient with 
gastric ulcer was given laser treatment but died, and one 
woman with acute gastritis diedafter medical treatment. 
Of the 2 patients with a malignant ulcer, one died. Table
(4.1) shows that in this study the mortality rate from
stomach bleeding was 8.8% and from a gastric ulcer 6.7%.
Twenty nine people suffered from a duodenal ulcer, 8 
of these exhibited severe bleeding. Six were treated by 
surgery, of whom one died; and 2 were treated by laser, 
of whom one died. One woman given medical treatment 
died. In total 3 people died from duodenal ulcer,
therefore the mortality rate from D.U. bleeding was 10%. 
No death was recorded from duodenitis. Tables 4.2 and
4.3 summarise the clinical course in those patients who 
died or required surgery. The case histories are 
outlined in Appendix 4.
4.5 Discussions
Clearly there are difficulties in drawing too many 
conclusions about UGIT bleeding from this group. The 
main difficulty relates to the selection process.
Recognition of a diurnal rhythm in fibrinolytic activity 
meant that only those patients available for sampling at 
9.00 a.m. could be included. This was not, therefore, a 
consecutive series and it is certain that seriously ill 
patients admitted and proceeding to surgery immediately 
were not included. It could not be claimed, then, that 
this series is typical of those admitted to the Royal 
Infirmary. If anything, it underestimates the severity
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of the condition ss seen et this hospital. A further* 
"skewing factor is that the hospital is a local referral 
centre for oesophageal varices patients.
However, the current series is not too dissimilar to 
previously reported series in terms of age, sex and site 
of bleeding. The incidence of bleeding from UGIT was 
higher in men than in women (prevalence 60% and 40% 
respectively). In mean the incidence of bleeding was 
commonest in young to middle age, but in females the 
incidence of bleeding increased. Almost certainly, for 
reasons already mentioned, this series underestimates the 
mortality of patients with UGIT bleeding admitted to this 
hospital.
The mortality from oesophageal varices was 33% in 
this study. In review studies, mortality from 
oesophageal varices varies considerably, ranging from 13% 
to 50% were observed: 14% by Alwmark et al (1982), 31%
by Kjargaard et al (1982), 21% by Barsoum et al (1982), 
32% by Palani et al (1982), 39% by Terblanch et al
(1981), 16% by Johnston and Rodgers (1973), 50% by
Raschke and Paquet (1973), 13% by Denck (1971).
In those with gastric ulcers, the mortality rate was 
7%. In review studies the mortality rates were fairly 
constant 11% (Barer et al 1982), 13.1% (Hunt et al 1983), 
13.9% (Vellacott et al 1982). One person died from
severe acute gastritis.
For duodenal bleeding, 3 people died from duodenal 
ulcer therefore, the mortality rate from duodenal ulcer
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bleeding was 10-6. In review studies the mortality was 
6.2% (Hunt et al 1983) and 9.8% (Vellacott et al 1982). 
No death was recorded from duodenitis.
Although survival in this series was similar to that 
reported by other groups it is almost certain that this 
is an underestimate.
As already mentioned in the introduction, endoscopy 
can define the source of UGIT bleeding in around 80-90% 
of cases, and in this study the source of bleeding was 
defined in 84% of the cases. This is satisfactory, 
particularly when it is recognised that, in the 122 
patients, 11 different endoscopists carried out the 
examinations. Six of these were surgeons or physicians 
in training. This accounts for some of the diagnostic 
categories identified by the endoscopist. For example, 
"gastric erosions" and "gastritis" are probably different 
interpretations of the same lesion. It was clearly not 
the function of the author to influence the 
endoscopists's assessment of the gastroscopic appearances 
and patients have been classified exactly as the 
endoscopist has described them. If "gastric erosion" 
and "gastritis" groups are combined, it makes little 
difference to the overall pattern of pathology.
A further difficulty relates to alcohol consumption 
and its measurement. Any attempt to measure alcohol 
consumption by asking the patient will inevitably be 
subject to bias. Patients may underestimate their
consumption, they may lie in an attempt to save face and
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occasionally, they may exaggerate their intake. The 
levels of intake chosen in this study (< lo units/week 
and > 10 units/week) are somewhat lower than those
normally taken to indicate problem drinking. This was 
done in an attempt to compensate for a systemic tendency 
to underestimate alcohol consumption. It is accepted 
that inaccuracy in the estimation of intake of alcohol 
will occur. Using this method, 60% of patients had been 
drinking in the week prior to admission.
A proportion of patients (22%) had liver disease. As 
already mentioned, this will affect some constituents of 
the clotting cascade. This will be dealt with in due 
course.
No mention has been made of the drug treatment given 
to these patients prior to sampling. Three of the 
oesophageal varices patients received somatostatin, all 
of the patients who had received blood were given 
cimetidine or ranitidine prior to sampling and no patient 
received prostaglandin agonists.
In summary, therefore, the patients recruited into 
the study were typical of other groups in terms of age, 
sex and pathology distribution. Mortality was also 
similar to that seen in other studies but there is a 
suspicion that the figures obtained underestimate the 
true mortality seen in Glasgow.
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CHAPTER V 
FIBRIN DEGRADATION PRODUCTS IN 
ACUTE UPPER GASTROINTESTINAL BLEEDING 
Investigation of the pattern of FDP in the blood of 
patients with UGIT bleeding occurred in three stages. 
Initially, serum FDP levels were measured in all 122 
patients described in the previous chapter. The standard 
Wellcome kit assay does not distinguish fibrinogen 
degradation products from cross-linked FDP and may be 
affected by clotting in vitro during preparation of serum 
(Nieuwenhuizen, 1987). Therefore an assay for plasma 
levels of cross-linked FDP using specific monoclonal 
antibodies (Dimertesst ELISA, AGEN) was evaluated 
retrospectively in stored plasma retained from patients 
in the prospective study (see section VI). The third 
part of this chapter stemmed from the realisation that 
the standard tests are time-consuming and require 
laboratory assistance. If high serum FDP levels actually 
predict a poor outcome, the test only has clinical value 
in so far as it is available to the clinician, on the 
ward, at all times of the day. The Thrombo-Wellcotest is 
a simple screening test for high FDP levels and again, 
its use was evaluated retrospectively in serum stored 
from the earlier testing.
5.1.1 Serum FDP (Wei3come FDP Kitj
At 09.00 a.m. on the morning after admission and 
before endoscopy, venous blood was taken from resting, 
fasting patients with minimal vein occlusion. Samples
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were treated as described in section II.
Analysis of FDP results was performed as follows
a) Anatomical Site of Bleeding
1) Oesophagus
2) Stomach
3) Duodenum
4) Other (undiagnosed site of haemorrhage)
b) Pathological Causes of Bleeding
1 - Oesophagitis
2 - Mallory Weiss Syndrome
3 - Oesophageal Varices
4 - Oesophageal Peptic Ulcer
5 - Gastritis
6 - Ca. Stomach
7 - Gastric Benign Ulcer
8 - Gastric Erosion
9 - Stomal Ulcer
10 - Duodenitis
11 - Duodenal Ulcer
c) Severity of Bleeding
1 - Patients who had not been transfused
2 - Patients who had a transfusion, without
surgery or death
3 - Patients requiring surgery, or patients who
died.
5*1•2 Results
Site of Bleeding
Table 5.1 shows the FDP results grouped according to
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Table 5.1 Measurement of F.D.P. in groups related to 
anatomical site of bleeding, (others = 20 
patients undiagnosed and two patients with 
stomal ulcer)
Site
of
Bleeding
Number
of
patients
Mean
Age
(year)
Mean
FDP
(pg/ml)
Median
FDP
(pg/ml)
SEM
FDP
(pg/ml)
Oesophagus 34 54 36 10 9.3
Stomach 34 56 39 7.5 2.3
Duodenum 32 51 22 10 6.0
Others 22 58 8 3.5 3.6
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clinical severity and indicating site of bleeding: Thirty 
four patients exhibited bleeding from the oesophagus, 34 
patients from the stomach, 32 patients from the duodenum, 
2 patients from a stomal ulcer and 20 patients were 
undiagnosed.
FDP was significantly higher in the groups with 
bleeding from the oesophagus, stomach or duodenum, 
compared to the group in which the site of bleeding was 
undiagnosed (Kruskal-Wallis test, p < 0.01). The FDP 
variations within the first 3 groups were not 
statistically significant.
b) Pathological Causes of Bleeding (Table 5.2)
Patients with oesophageal varices or gastritis tended
to have higher levels than the other pathological groups.
No serious conclusions can be drawn because of small 
numbers in each diagnostic group.
c) Severity of Bleeding (Figure 5.1, Table 5.3)
In the first group (no transfusion), the FDP levels 
were usually normal. They were higher in group 2 
(patients who subsequently required a blood transfusion) 
and highest in group 3 (those who subsequently required 
surgery or died). The Kruskal-Wallis test was highly 
significant (p <0.001). The Wilcoxon Mann-Whitney tests 
showed significant differences between group 1 and group 
2 (p = 0.05) , group 1 and group 3 (p = 0.01) and group 2 
and group 3 (p = 0.01).
d) FDP level according to medical therapy (Table 5.4) 
Three oesophageal varices patients received
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Table 5.2 Measurement of FDP in groups related to 
pathological cause of bleeding in upper 
gastrointestinal tract.
Pathological No. of Mean Mean Median SEM
Cause patients Age FDP FDP FDP
- (Years) ( jug/ml) (/ig/ml) (jig/ml)
Oesophagitis 3 55 5 5 0
M.W. 12 50 13 5 6.6
Varices 15 58 67 30 17.7
Oesophageal Ulcer 4 64 11 10 3.8
Gastritis 12 43 79 6 64.9
Ca. Stomach 2 64 45 10 35.0
Gastric Ulcer 15 51 15 8 5.1
Gastric Erosion 5 50 11 7 4.1
Stomal Ulcer 2 41 3.75 2.5 1.3
Duodenitis 3 43 5 4 1.2
Duodenal Ulcer 29 52 24 10 6.5
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Figure 5.1 Relationship between F.D.P. and severity of 
bleeding. First group: no blood
transfusion; Second group: with blood 
transfusion; Third group: required surgery 
or died. Site of bleeding as follows: 
Stomach 
Duodenum 
Oesophagus
Others (undiagnosed, and 2 patients 
patients with stomal ulcer).
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Table 5.3 Relationship between F.D.P. and severity
of bleeding. First group: no blood
transfusion; second group: with blood
transfusion; third group: required surgery
or died.
Groups of 
Patients
No. of 
patients
Mean
Age
(years)
Mean
F.D.P.
(jig/ml)
Median
F.D.P.
(jig/ml)
S.E.M.
F.D.P.
(pg/ml)
1 Non-
Transfusion 65 56 8.2 5 5.1
2 Transfusion 37 51 15 8.8 3.3
3 Surgery/
Died 20 64 114 80 6.0
Kruskal-Wallis one way analysis of variance group 3 > 
group 1 or 2 p <.001.
Wilcoxon rank sum test 1 vs 2 p = 0.05
1 vs 3 p = 0.01
2 vs 3 p = 0.01
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Table 5.4 This contingency table relates the numbers 
of patients receiving cimetidine to the 
presence or absence of elevated FDP levels. 
Cimetidine appears to have no effect on FDP 
level.
FDP < 10 jig/ml FDP > 10 p.g/ml
Cimetidine 45 24 69
No cimetidine 40 13 53
85 / 37 122
p > 0.5 X2 = 0.07 D.F. = 1 N.S.
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somatostatin before samples. This number is too small 
to permit a genuine assessment or to assess the effect of 
this drug on FDP level although it did not appear to have 
any effect. 69 of the 122 patients had received 
cimetidine before sampling. The relationship between 
cimetidine and raised FDP is shown in table 5.2. There 
appeared to be no association between raised FDP and 
cimetidine intake. No patient received prostaglandin 
agonists.
e) Multivariate Analysis
The association between FDP and outcome may reflect 
mutual associations with other variables of prognostic 
importance. Therefore, to determine whether FDP were of 
independent prognostic value, a multivariate logistic 
regression analysis of good outcome (no transfusion, n = 
64) versus poor outcome (transfusion, surgery or death, n 
= 58) was performed, including not only FDP levels but 
also other variables shown to be prognostic variables in 
the literature (age, pulse rate, diastolic blood 
pressure, haemoglobin level, site of bleeding, and 
stigmata of active bleeding at endoscopy).
After including these variables, the serum FDP level 
was still of independent prognostic significance (p < 
0*025), as were pulse rate (p <0.04) and age (p <0.05).
Although the site of bleeding was not predictive of 
outcome, patients with oesophageal varices had high FDP 
levels (Figure 5.1). Therefore the analysis was repeated 
after excluding the oesophageal group, and the
- 154 -
qualitative results were identical. Serum FDP level was 
an important independent prognostic factor ( p < 0.001) 
as was haemoglobin level (p < 0.001). Age (p = 0.05)
and stigmata of bleeding (p = 0.08) were of borderline 
significance. It was therefore concluded that FDP were 
of prognostic significance and that this was not only due 
to the high FDP levels in the oesophageal varices group.
5.2 Study of Plasma D-Dimer in Acute UGIT Bleeding
5.2.1 Methods and Patients
Stored plasma samples were available from 62 patients 
in the prospective study. The conditions under which 
they were taken have already been described (section 
II).
Plasma D-dimer was measured using an ELISA assay 
(AGEN, Parsippany, New Jersey) as described in Chapter 
II.
Results were analysed as follows (Table 5.5):
a) Severity
Group 1 - No transfusion
Group 2 - Blood transfusion but no surgery or
death
Group 3 - Treated by surgery or died
b) Site of Bleeding 
Oesophagus 
Stomach 
Duodenum
Others (including undiagnosed patients)
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Table 5.5 Relationship between D-dimer and severity of 
bleeding.
Group 1: patients with no blood transfusion 
Group 2: patients with blood transfusion but 
no surgery or died 
Group 3: patient requiring surgery or died
Groups No. of 
patients
Mean
age
(Years)
Mean
D-dimer
(ng/ml)
Median
D-dimer
(ng/ml)
SEM
D-dimer
(ng/ml)
Group 1 32 54 130 80 15.9
Group 2 20 56 138 94 32.2
Group 3 10 58 621 460 132.5
Kruskal-Wallis one way analysis of variance Gp 3 > Gp 2 
or Gp 1. p < 0.05.
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5.2.2 Results
Plasma D dimer levels were measured in 62 patients 
with upper GIT bleeding. Their age ranged from 30 years 
to 80 years, with a mean of 52 years and a median of 54 
years. This number comprised 36 (58%) men and 26 (42%) 
women. Twelve patients were bleeding from the oesophagus: 
4 patients with Mallory-Weiss tears; 2 patients with 
oesphageal varices and 1 patient with oesophagitis.
Twenty two patients were bleeding from the stomach: 
12 patients with gastric ulcer, 4 patients with 
gastritis, 2 patients with carcinoma of stomach and 4 
patients with gastric erosions.
Eighteen patients were bleeding from the duodenum; 17 
patients from duodenal ulcer and 1 patient from 
duodenitis.
Mean levels of D-dimer were similar in Groups 1 and 
2, but significantly elevated in Group 3 (Kruskal-Wallis 
test, p. < 0.05) (Table 5.6, Fig. 5.2).
5.3 Study of Serum F.D.P. Measured by a Rapid Screening 
Method (Thrombo-Wellcotest) in Acute UGIT Bleeding
5.3.1 Methods and Patients
Stored sera were available from 36 patients with 
haematemesis (with or without melaena) and melaena. 
Patients who had been treated by antifibrinolytic drugs, 
and those with blood dyscrasias were excluded.
The test used is a rapid, latex test for detection of 
raised fibrinogen degradation products (over 10 ug/ml). 
The Thrombo-Wellcotest (Wellcome, Beckenham, Kent) is
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Table 5.6 F.D.P. (Latex test) was performed on 36 
patients with upper gastrointestinal 
bleeding.
Result Total Not requiring Requiring
Test Patient surgery surgery or died
Positive 7 2 5
Negative 29 29 0
Fisher's exact test p < 0.0001.
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designed as a slide agglutination method in which one 
drop of serum sample and one drop of latex suspension are 
mixed for a period of two minutes by gentle rocking. An 
agglutinated pattern is seen at the end of the test 
period (Chapter 2). It is ideally suited for use on the 
ward.
5.3.2 Sample of blood
As Section 5.1.
5.3.3 Results (Table 5.6)
Thirty-six patients were included in the 
Thrombo-Wellcotest study. One patient had oesophagitis; 
2 patients Mallory-Weiss syndrome; 1 patient had 
oesophageal varices, and 1 patient had an oesophageal 
peptic ulcer. From those who had bleeding from the 
stomach, 3 patients had gastritis, 8 patients gastric 
ulcer, and 4 patients gastric erosion. Thirteen gastric 
ulcer, and 4 patients gastric erosion. Thirteen patients 
had a duodenal ulcer and 1 had a stomal ulcer. In 2 
patients the site of bleeding was undiagnosed.
Seven patients showed a positive test for raised 
fibrinogen degradation products; of whom 5 patients had 
surgery or died (Fisher's test, p < 0.0001). The first 
patient had a gastric ulcer and died without surgery. The 
second patient had acute gastritis owing to an overdose 
of paracetamol and died after medical treatment. The 
third and fourth patients who had a duodenal ulcer were 
treated by surgery; and the fifth patient whose duodenal 
ulcer was treated by laser, died from severe bleeding.
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Of the other 2 patients who had positive tests but no 
surgery, one had severe bleeding and received 6 units of 
blood. Endoscopic diagnosis showed a posterior large 
gastric ulcer with necrotic tissue in the ulcer and a 
visible vessel. The indications for surgery were high, 
but his general condition was not satisfactory for 
operation. The patient was put on medical treatment and 
survived. The second patient had a duodenal ulcer.
5.4 Discussion
Poller (1979) described raised serum FDP levels in a 
percentage of a small series of patients with acute upper 
gastro-intestinal bleeding. The main finding of the 
current, much larger study was that elevated FDP levels 
were related to the severity of bleeding (Fig. 5.1). The 
upper limit of the "normal range" for the Wellcome FDP 
kit varies from 5-10 ug/ml according to laboratory (Lowe 
and Prentice 1980) and in this laboratory is less than 5 
ug/ml. Levels of 10 ug/ml or above were observed in 
above were observed in 18 of 64 patients in Group 1 (no 
transfusion), 21 of 38 patients in Group 2 (transfusion 
but no surgery or death), but in all 20 patients in Group 
3 (surgery or death) Fig. 5.1).
Several possible explanations for this prognostic 
value of FDP levels can be considered.
1) Raised serum FDP levels might result from 
absorption into the bloodstream of degraded, soluble 
fragments of blood clot in the lumen of the 
gastro-intestinal tract. The greater the blood loss,
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therefore the higher the serum FDP level may be as a 
result of the larger amount of blood in the gut.
2) Raised serum FDP levels might arise as a result 
of blood transfusion, e.g. due to stimulation of 
intravascular coagulation and hence fibrinolysis by 
haemolysed red blood cells. This possibility has been 
addressed in the next chapter.
3) Raised serum FDP levels were higher in Group 3 
because of their association with certain sites or 
pathologies of bleeding (or with other factors such as 
age) which have a high risk of death or surgery. This may 
be part of the explanation. Figure 5.1 shows that most 
patients in whom no site of bleeding was identified at 
endoscopy had normal FDP levels (less than 10 ug/ml). 
Conversely, the highest FDP levels were found in patients 
with oesphageal varices, who have a high risk of death or 
surgery (Fig. 5.1) This finding is consistent with the 
study of Bertaglia et al (1983), who found higher levels 
of serum FDP in 11 patients with bleeding oesphageal 
varices (mean 30 ug/ml) compared to 13 patients with 
cirrhosis without bleeding (mean 7 ug/ml). Bertaglia et 
al (1983) suggested several mechanisms by which 
intravascular coagulation might be stimulated in 
cirrhosis, and these are discussed further in Section IX. 
However, patients with bleeding from the stomach or 
duodenum who were in Group 3 also had higher levels of 
FDP than patients bleeding from similar sites in Groups 1 
and 2 (Fig. 5.1). Furthermore, multivariate analysis
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showed independent predictive value of FDP.
4) Raised serum FDP levels in Groups 2 and 3 
reflect increased fibrinolytic activity which promotes 
continued bleeding by digesting the haemostatic fibrin 
plugs at the site of bleeding. This possibility is 
consistent with the metanalysis of the results of 
controlled trials of the anti-fibrinolytic drug, 
tranexamic acid, which showed its efficacy in reducing 
re-bleeding and mortality (Henry and Collins 1988).
The upper limit of the "normal range" for the plasma 
D-dimer level in this laboratory is 300 ng/ml. Only one 
patient in group 1 and one patient in group 2 had raised 
levels, whereas 8 of the 10 patients in group 3 had 
raised levels (Figure 5.2). These results therefore show 
a similar prognostic value for plasma D-dimer levels in 
acute upper gastrointestinal bleeding as for the 
traditional serum FDP test. Furthermore they indicate 
that the raised FDP levels reflect lysis of cross-linked 
fibrin, rather than non-cross-linked fibrinogen. However 
the test does not distinguish intravascular, haemostatic 
fibrin from extravascular fibrin (e.g. fibrin blood clot 
within the lumen of the gastrointestinal tract).
The results of this pilot study suggests that plasma 
D-dimer levels (which can also be measured rapidly by a 
latex test) be studied in a larger, prospective study to 
establish their prognostic value in acute upper 
gastrointestinal bleeding.
However, the latex test used in the third study is a
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simple and rapid test, which takes only two minutes, and 
which might allow the test to be performed in the 
investigation of all patients who have upper GIT 
bleeding.
All patients who were negative avoided surgery and 
none died. From the 7 patients who were positive, 5 
patients required surgery or died. This pilot study is 
consistent with the results of the quantitative study of 
FDP levels (Section 5.1), in which FDP levels over 10 
ug/ml were associated with a high risk of surgery or 
death. A further, larger prospective study is suggested 
to evaluate the prognostic significance of this simple 
test.
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CHAPTER VI
STUDY OF PLASMA PLASMINOGEN ACTIVATOR LEVELS IN 
ACUTE UGIT BLEEDING
6.1 Introduction
Patients with acute UGIT bleeding have been shown in 
Chapter V to have increased serum F.D.P. and, presumably 
elevated fibrinolysis.
It is therefore possible that systemic plasma 
plasminogen activator levels are raised in such 
patients.
Plasma plasminogen activator activity was therefore 
studied by Fibrin Plate Lysis Area (F.P.L.A.) produced by 
the plasma euglobulin fraction. This test measures the 
global plasminogen activator level in plasma including 
the effects of any inhibitors in the euglobulin 
precipitate (Chapter II).
6.2 Patients and Methods
F.P.L.A. was measured in all 122 patients who were 
studied prospectively, whose clinical features were 
described in Chapter IV. Method of blood sampling and 
assay methods are as described in Chapter II.
6.3 Results
In the prospective study 122 patients with upper GIT 
haemorrhage were included. Their ages ranged from 19 
years to 80 years, with a mean of 54 years and median of 
56 years.
This number comprised 73 (60%) men and 49 (40%)
women.
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The mean level of F.P.L A. in the whole group was 70 
+ SD 40 mm2. This is very similar to the results for a 
previous group of patients of similar age studied by the 
same method in Glasgow Royal Infirmary at the same time 
of day prior to elective surgery (Blarney et al, 1984). 
These results suggest that acute UGIT bleeding does not 
result in any general change in basal plasma plasminogen 
activator levels.
The F.P.L.A. levels did not differ according to site 
of bleeding: see Table 6.1.
Furthermore, there were no significant differences 
between groups when classified as to the type of 
pathology (see Table 6.2).
Patients were divided by outcome into 3 groups:-
(1) Patients who had no transfusion 
(65 patients)
(2) 37 patients who required blood transfusion
but did not die
(3) 20 patients who either had surgery or died
Mean F.P.L.A. levels were not significantly different
between group 1 and group 2 (p >0.3), or between group 2 
and group 3 (p > 0.2). However, group 3 was
significantly lower than group 1 (p = 0.02). (Table 6.3 
and Figure 6.1).
6.4 Discussion
The fibrin plate lysis area of the euglobulin 
fraction of plasma is a global measurement of plasma
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Table 6.1 Relationship between F.P.L.A. and site of
bleeding (oesophagus, stomach, duodenum and 
others).
Site of 
Bleeding
No. of 
patients
Mean
age
(years)
Mean
FPLA
(mm2)
S.E.M.
FPLA 
(mm2 )
Median
FPLA
(mm2)
Oesophagus 34 54 74.9 6.7 78
Stomach 34 56 62.6 6.5 64
Duodenum 32 51 67.9 7.1 70
Others* 22 58 80 9.9 78
* Others = Undiagnosed patients and 2 patients with 
stomal ulcer.
(Kruskal-Wallis one way analysis of variance). No 
significant differences between groups.
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Table 6.2 F.P.L.A. in relation to pathological under­
lying cause of bleeding.
Cause No . of 
of patients 
bleeding
Mean
Age
(years)
Mean
FPLA
(mm2)
SEM 
FPLA 
(mm 2)
Median
FPLA
(mm2)
Oesophagitis 3 55 47 24.8 17
M.W. 12 50 74 13.9 95
Oesophageal
varices 15 58 80 9.0 75
Oesophageal
ulcer 4 64 64 14.5 54
Gastritis 12 43 77 11.3 78
Ca. stomach 2 64 67 10.6 56
Gastric ulcer 15 51 51 9.3 40
Gastric erosion 5 50 57 20.1 38
Stomal ulcer 2 41 107 38.2 69
Duodenitis 3 43 94 31.2 64
Duodenal ulcer 29 52 65 7.2 68
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Table 6.3 Relationship between F.P.L.A. and severity of 
bleeding (not transfused, transfused and 
surgery/died).
No. of Mean S.E.M. Median
Group Patients FPLA FPLA FPLA
' (mm2)
O
(mm ) (mm2)
1) Non­
transfusion 65 77.1 9.7 78
2) Transfusion 37 67.3 12.2 74
3) Surgery/Died 20 55.1 13.4 60
(Kruskal-Wallis one way analysis of variance).
Group 1 v Group 2
Group 2 v Group 3 v
Group 1 v Group 3 p <0.02.
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Figure 6.1 F.P.L.A. and severity of bleeding divided 
into three groups
(1) patients without transfusion
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(3) patients who had surgery or died.
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plasminogen activators, as well as their inhibition by 
plasminogen activator inhibitors (Brommer, 1988). It may 
therefore be useful as an estimate of the "fibrinolytic 
potential" balance between plasminogen activators and 
their inhibitors (Brommer, 1988). In the present study, 
the fibrin plate lysis area was determined to test the 
hypothesis that a systemic increase in plasminogen 
activator levels might be present in patients with acute 
upper gastro-intestinal bleeding and might correlate with 
persistent bleeding. This hypothesis was suggested by 
previous studies showing fibrinolytic activity in the 
stomach (Poller, 1979).
Fibrin plate lysis area levels in the whole group of 
patients with acute gastrointestinal bleeding were 
similar to levels found by the same method in a group of 
patients of similar age, studied prior to elective 
gastrointestinal surgery (Blarney et al, 1984). This 
finding suggests that, as a group, patients with acute 
gastrointestinal bleeding do not have a significant 
increase in plasma fibrinolytic potential. The increased 
levels of F.D.P. observed (described in Section V) must 
therefore result from increased local fibrinolytic 
activity.
Fibrin plate lysis area levels were not significantly 
associated with site of bleeding (i.e. oesophagus, 
stomach, duodenum, or the undiagnosed group). This 
finding suggests that no particular upper
gastrointestinal site of bleeding is associated with
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increased plasma fibrinolytic potential. Similarly, no 
significant association with the pathological lesion was 
observed.
A significant association was observed between 
severity of bleeding and fibrin plate lysis area. This 
finding is a determinant of prognosis in acute upper 
gastrointestinal bleeding. A lower fibrinolytic 
potential in the poorest outcome group (Group 3) was 
observed when compared to the best outcome group (Group 
1). Two possible explanations are suggested. Firstly, 
plasminogen activators may have been consumed in 
adsorption to local fibrin in Group 3 (which had the 
highest FDP level, see Section V). The second, more 
probable, explanation is that the ill patients in Group 3 
had the highest levels of the acute-phase reactant, 
plasminogen activator inhibitor (PAI). This would be 
similar to the finding that, in patients with septic 
shock, those with high levels of plasma plasminogen 
activator levels had the poorest outcome (Kruithof, 
1988). Measurement of PAI levels would be required to 
test this hypothesis and, at the time of study, such 
tests are not available in this laboratory.
In summary, plasma plasminogen activator levels were 
poorly related to site, pathology, and outcome of acute 
upper GI bleeding with the exception that the lowest 
levels were found in the group with poorest outcome.
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CHAPTER VII 
THE EFFECT OF TRANSFUSION OF STORED BLOOD 
ON THE FIBRINOLYTIC SYSTEM
7.1 Introduction
As mentioned in the previous section, one explanation 
for the finding that the more severely ill patients had 
elevated indices of fibrinolysis is the possibility that 
stored blood either contains products of fibrinolysis or 
itself stimulates fibrinolysis. There is no evidence in 
the literature that this is the case. However, it was 
necessary to check this possibility and an appropriate 
study was carried out.
7.2 Aim of Study
The aim of this study was to assess the effect of 
blood transfusion on the fibrinolytic system as measured 
by serum F.D.P. levels and plasminogen activator levels 
(fibrin plate lysis area).
7.3 Patients and Methods
A review of the patients included in the large study 
reported in chapter III showed that at the time of 
sampling, no patient in the study had received more than 
four units of blood. A number of patients who were 
receiving blood transfusion for elective reasons were 
recruited. Ten patients (four females and six males) 
were recruited. Six patients had been admitted 
electively for assessment of advanced colon cancer and 
were being considered for chemotherapy. One patient had 
breast cancer, two patients had oesophageal varices and
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had been admitted for elective sclerotherapy. 
Accordingly, they were stable at the time of admission. 
On patient was admitted for investigation of anaemia and 
the subsequent diagnosis was considered to be 
diverticular disease.
No patient had active bleeding at the time of 
admission. None had a blood dyscrasia and no patients 
were on anticoagulants at the time of the study.
All patients were judged by the clinicians in charge 
of their cases to require blood transfusion and the 
number of units transfused was recorded.
Blood samples were taken as previously described. All 
patients wre fasting at the time of sampling which was 
09.00 a.m. Transfusion was then started. In nine 
patients, the time of the post transfusion sample was at 
least twelve hours later and this sample was taken 
immediately transfusion was stopped. In one patient 
only one unit was transfused and sampling took place six 
hours after the pre-transfusion sample.
Standard methods were used for measurement of F.D.P. 
in serum and the fibrin plate lysis area was used to 
measure plasminogen activation (see section II).
7.4 Results.
The results of the F.D.P. levels in serum are shown 
in table 7.1 and the results of the F.P.L.A. test on 
plasma are shown in table 7.2. No significant 
differences are noted in either F.D.P. level or F.P.L.A. 
after transfusion in stable patients.
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Table 7.1 10 patients with blood transfusion: serum
F.D.P. before and after blood transfusion.
No. of 
patient
Blood
tranfused
(units)
F.D.P. before 
transfusion 
(jig/ml)
F.D.P. after 
transfusion 
(pg/ml)
1 4 40 40
2 2 80 80
3 3 20 20
4 2 11.2 20
5 2 3.5 5
6 1 2.5 2.5
7 3 20 20
8 2 10 10
9 2 5 5
10 3 10 10
Median 10.6 15.0
S.D. 23.75 23.42
Non significant Wilcoxon signed rank test.
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Table 7.2 10 patients with blood transfusion: plasma
F.P.L.A. before and after blood transfusion.
No. of 
Patients
Blood
Transfusion
(unit)
Before
Transfusion
mm 2
After
Transfusio:
mm2
1 4 94.9 86.6
2 2 0 0
3 3 63.6 132.7
4 2 136.8 169.63
5 2 78.5 63.6
6 1 50.2 38.5
7 3 78.5 95
8 2 50.2 54
9 2 106 113
10 3 78.5 83.6
Median 78.5 85.1
S.D. 36,79 48.43
Non significant Wilcoxon signed rank test.
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7.5 Discussion
The suitability of these patients to act as subjects 
for the study of fibrinolytic activity in the post 
transfused state should be commented upon. Firstly, it 
should be made clear that these patients were not 
intended to be "controls" for the UGIT bleeding group. It 
was necessary to find patients receiving blood for 
clinical reasons (since there are obvious ethical 
constraints preventing the use of volunteers willing to 
be transfused homologous blood). Those patients had to 
receive several units of blood and obviously 
post-operative patients who might still have activated 
fibrinolysis were unacceptable. Patients with profound 
anaemia seemed to be the most acceptable subjects.
In ten patients who were stable at the time of 
sampling, no significant increase in FDP level was noted
after transfusion of up to four units of blood. The
range of level seen in these patients was from 2.5 to 80 
ug/ml with a median of 10.6 ug/ml. This is comparable 
to the levels found in the survey of bleeding patients 
where patients with non-variceal bleeding had median
values of 10 ug/ml when the bleeding was from a duodenal 
ulcer. The ten patients reported here had similar 
amounts of blood given to them as in the duodenal ulcer 
group (although the UGIT bleeding patients went on to
have more blood on average) and there was no evidence of 
alteration of serum FDP level. The one patient who had 
post-transfusion sampling carried out in the afternoon
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when diurnal variation might have been expected to 
produce a higher value had identical figures for both pre 
and post-transfusion samples.
Similarly, the patients had FPLA measurements similar 
to those found in the least ill of the UGIT bleeding 
patients. The median FPLA was 78.5 mm2 in these ten 
patients while it was 68 mm2 in the bleeding duodenal 
ulcer patients. In the bleeding patients who did not 
require transfusion, median FPLA was 77.1 mm2. In terms 
then of the levels of the indicators measured, it seems 
that the present group of ten patients were comparable 
with the less ill of the study group.
Apart from obvious differences in pathology, the main 
source of a false negative result in this study would be 
the possibility that a slower rate of transfusion in the 
electively transfused patients would allow clearance of 
FDP and therefore mask the process of fibrin breakdown. 
Overall, it seems acceptable to conclude that the 
elevated indicators of fibrinolysis seen in the bleeding 
group are not due to the transfusion of stored blood.
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CHAPTER VIII 
FIBRINOLYTIC ACTIVITY IN PATIENTS WITH 
LIVER DISEASE
8.1 Introduction
It has already been argued in previous sections that 
increased fibrinolytic activity in vivo (raised plasma 
FDP level) is indicative of severity in patients with 
UGIT bleeding and that, by itself, the FDP level is a 
good predictor of outcome in these patients. Inevitably a 
series of UGIT bleeding patients in Glasgow will include 
a large percentage of patients with oesophageal varices. 
This is especially true of the Royal Infirmary because 
the treatment of this condition is a special interest of 
the University Surgical Unit in this hospital and it acts 
as a regional referral centre, accruing patients from all 
the surrounding Health Board areas.
It might be argued that the oesophageal varices 
patients in the study might have elevated FDP levels as a 
result of their liver disease, and because the poor 
prognosis group contained several such patients, perhaps 
they had a confounding effect on the results. This 
possibility is unlikely in view of the fact that the 
multiple logistic regression analysis reported in section 
V showed that FDP level was an independent and 
significant predictor of risk and that this effect was 
greater than that of site of bleeding. However, the 
effect of liver disease on fibrinolysis is well 
documented.
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Accordingly, it was decided to carry out a 
prospective study of fibrinolytic activity in patients 
with proven cirrhosis, sample in the chronic phase and if 
possible in the acute phase of further active bleeding.
8.2 Patients and methods
54 patients with biopsy proven cirrhosis of the liver 
were recruited into this study. All patients were 
attending the University Department of Surgery on a 
regular basis for chronic sclerotherapy to oesphageal 
varices. Clinical examination, including assessment of 
severity of hepatic failure using Child's classification 
(Pugh et al 1973), was carried out on each patient. 
Fasting blood samples were taken at 09.00 a.m. on the 
morning of admission before endoscopy and before 
sclerotherapy. No patient had bled in the month before 
recruitment. Patients in this group were followed 
prospectively and a proportion of these sclerotherapy 
patients were admitted subsequently as a result of UGIT 
bleeding. Ten patients with acute UGIT bleeding due to 
oesophageal varices were admitted from the chronic 
sclerotherapy programme and, therefore, they had results 
of FDP and FPLA test available both pre and post 
haemorrhage.
Blood samples were taken and assays carried out for 
serum FDP and plasma FPLA as already described in Chapter 
II. Results were compared to the 10 healthy controls 
previously described, as well as to the laboratory normal 
range.
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Table 8.1 Modified Child's classification
Score 1 2 3
Ascites absent slight moderate
Encephalopathy absent minimal severe
Bilirubin
(umol/1) < 34 34-51 > 51
Albumin (g/1) > 35 28-35 < 28
Prothrombin time
(seconds prolonged) 1-4 4-6 > 6
For each characteristic recorded, patients score as
indicated
Grade A = < 6
B = 7 - 9 
C = > 10
(Pugh et al 1973)
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8.3 Results
Of the 54 patients admitted for elective
sclerotherapy, there were 37 men and 17 women. The 
median age was 61 years with range from 31 to 84 years. 
The results of the laboratory investigations carried out 
on these patients are shown in table 8.2 Most 
conventional indicators of liver function were normal or 
close to normal reflecting patient selection for chronic 
sclerotherapy.
Serum FDP levels in patients with cirrhotic liver 
disease showed significant differences between the 3 
groups (Fig. 8.1, Table 8.3). The median values of
grades a, b and c were 5 ug/ml, 10 ug/ml and 25 ug/ml
respectively. Grades a or b did not show a significant
increase compared to normal values or to each other, but 
for groups b and c the difference between the means was 
highly significant (p < 0.01) (Wilcoxon rank sum test).
F.P.L.A. levels were significantly higher in patients 
with liver cirrhosis compared to expected normal values, 
but there was no significant difference (p > 0.1) between 
Child's grades (Table 8.4, Figure 8.2). The median 
F.P.L.A. levels of grades a, b and c were 95 mm2, 95 mm2 
and 98 mm2 respectively.
Tables 8.5 and 8.6 show the mean levels of FDP and 
FPLA according to pathological type of cirrhosis. There 
were no significant differences between these groups: 
however, there were few subjects in each of the 3 gruops 
with non-alcoholic cirrhosis.
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Table 8.3 Child's Classification and measured mean
serum FDP in stage A, B, C in patients with 
liver cirrhosis
Child's
Stages
No. of 
Patients
Mean
Age
Years
Mean
F.D.P.
ug/ml
SEM
F.D.P.
ug/ml
Median
F.D.P.
ug/ml
A 14 56 8
00•o 5
B 21 55 13 0.4 10
C 19 57 50
CO•
CM 25
Normal 10 30 3.4 0.7 2.5
Laboratory normal range < 10 ug/ml.
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Table 8.4 Child's Classification and mean F.P.L.A. in
Stage A, 
cirrhosis
B, C in 
•
patients with liver
Child's
Stages
No. of 
Patients
Mean
Age
Years
Mean
F.P.L.A.
.2mm^
SEM
F.P.L.A. F
2mmr
Median
.P.L.A.
2mm^
A 14 56 98 0.8 95
B 21 55 97 0.9 95
C 19 57 107 1.6 98
Normal 10 30 70 3.2 60
Laboratory normal range 47-121 mm2, mean 79 mm2.
Figure8.2 
F.P.L.A. 
in 
patients 
with 
portal 
hypertension 
compared 
to 
controls. 
The 
portal 
hypertension 
patients 
have 
been 
split 
into 
3 
groups 
based 
on 
the 
modified 
Child’s 
classification.
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Table 8.5 Relationship between serum F.D.P. and
pathological diagnosis of liver cirrhosis.
Causes No. of 
Patients
Mean
Age
Years
Mean
F.D.P.
(pg/ml)
SEM
F.D.P.
(jig/ml)
Median
F.D.P.
(}ig/ml)
Alcoholic
cirrhosis 36 55 13.5 1.9 10
Cryptogenic
cirrhosis 8 66 4 0.6 3.5
Primary
biliary
cirrhosis 6 64 23 6.2 15
Primary
sclerosing 
cholangitis 4 50 10 0 10
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Table 8.6 Relationship between F.P.L.A. and
pathological diagnosis of liver cirrhosis.
Causes No . of Mean Mean SEM Median
Patients Age FPLA FPLA FPLA
Years
1
1
(mm.^ ) (mm^)
Alcoholic
cirrhosis 36 55 104 3.5 98
Cryptogenic
cirrhosis 8 66 99 2.4 92
Primary
biliary
cirrhosis 6 64 97
IS•o 96.5
Primary
sclerosing
cholangitis 4 50 135 1.2 120
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Of the patients on the chronic sclerotherapy 
programme, ten patients were admitted with acute bleeding 
during the period of this investigation and were 
available for study. Their ages ranged from 35 to 71 
with a median of 61 years. There were 7 men and 3 
women.
Three of these patients settled after tamponade and 
had elective sclerotherapy carried out on the same 
admission. Seven patients failed to stop bleeding with 
a Minnesota tube and required emergency sclerotherapy. 
Two of these patients continued to bleed and died of 
haemorrhage. The FDP level and FPLA results are shown in 
table 8.7 and Figure 8.3.
The median FDP in this group was 20 ug/ml and the 
median FPLA was 95 mm2. FDP level was significantly 
greater than that seen in the blood samples taken from 
these patients before haemorrhage (p < 0.01 Wilcoxon rank 
sum test for matched pairs).
8.4 Discussion
This study confirms that patients with hepatic 
cirrhosis and portal hypertension have elevated levels of 
plasma plasminogen activator activity (increased FPLA 
levels) , as well as increased levels of serum FDP. Such 
findings have been previously reported in some other 
small series (Brozovic 1987). The present study shows 
that raised FDP levels are related to the severity of 
cirrhosis, being most marked in Child's grade C. While a 
trend to higher FPLA levels in Child's grade C was
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Table 8.7 Ten patients with acute oesophageal varices 
bleeding and measurement of serum F.D.P. and 
plasma F.P.L.A. with mention of diagnosis of 
liver disease
No. Sex Diagnosis Serum Plasma
F.D.P. F.P.L.A.
(ug/ml) (mm2)
1 M Alcoholic cirrhosis 20 90
2 M Alcoholic cirrhosis 160 50
3 M Primary sclerosing
cholangitis 10 95
4 M Alcoholic cirrhosis 10 130
5 F Alcoholic cirrhosis 20 95
6 F Primary biliary cirrhosis 40 113
7 M Alcoholic cirrhosis 5 131
8 F Primary biliary cirrhosis 40 93
9 M Alcoholic cirrhosis 20 113
10 M Alcoholic cirrhosis 160 50
Mean 48.5 96.0
SD 59.9 28.4
Median 20 95
ug/ml
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140 -
120 -
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Figure 8.3 Ten patients with liver cirrhosis: serum
F.D.P. pre and post bleeding from 
oesophageal varices.
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observed, this was not statistically significant.
The raised FPLA levels in cirrhosis may be due to 
impaired hepatic clearance of plasminogen activators 
(Balkuv-Ulutin, 1978), or to enzymes other than plasmin, 
such as proteases released from blood cells (Latallo et 
al, 1978). It is also possible that low levels of the 
recently described plasminogen activator inhibitor type I 
(PAI-1), which is produced by hepatocytes, endothelial 
cells and platelets (Kruithoff, 1988) may contribute to 
the raised FPLA levels.
The association of raised FDP levels with severity of 
cirrhosis suggests that, as with other haemostatic 
changes (Brozovic, 1987), increased degradation of fibrin 
reflects the severity of liver damage. The median FDP 
level in patients with Child's grade C (25 ug/ml) is 
similar to that reported in the study of Bertaglia et al 
(1983). Patients in Child's grade C are also more likely 
to have acute variceal bleeding but when bleeding 
supervened in the group of ten patients a further rise in 
serum FDP was noted.
The relationship between severity of cirrhosis, acute 
bleeding, and increased FDP levels may be interpreted in 
several ways. Increased FDP levels may be the result of 
the disturbances in coagulation and fibrinolysis in 
severe cirrhosis, or may result from absorption of lysed 
clot from the gut in patients with acute bleeding. On the 
other hand, increased fibrinolytic activity may promote 
breakdown of haemostatic plugs in oesophageal varices,
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promoting bleeding. Bertaglia et al (1983) found that 9 
of 11 patients with bleeding oesophageal varices due to 
hepatic cirrhosis had raised serum FDP levels using the 
same Wellcome method. These authors suggested several 
other possible mechanisms for activated coagulation and 
fibrinolysis in such patients, including release of 
thromboplastins from necrotic liver cells, endotoxaemia; 
reduced hepatic clearance of activated coagulation 
factors; reduced antithrombin III levels, and stagnation 
of blood in collaterals.
Antifibrinolytic drugs have sometimes been used in 
treatment of bleeding varices (Ratnoff 1977) but no large 
studies have been performed. A recent textbook of 
medicine (Weatherall et al, 1987) and a recent review of 
the management of bleeding due to portal hypertension 
(Burroughs, 1988) do not even mention this approach to 
treatment. Further trials of prevention and treatment 
of bleeding from oesophageal varices are certainly 
required (Burroughs, 1988). The results of the present 
study are consistent with a role for fibrinolysis, and 
suggest evaluation of antifibrinolytic agents in such 
patients.
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CHAPTER IX 
DISCUSSION
Although individual studies in this thesis have been 
discussed as part of the relevant chapter, the nature of 
the problem addressed requires some general points to be 
made in a final summing up. The management of UGIT 
bleeding remains one of the most complex and difficult 
areas in modern surgery. It is a subject which often 
causes controversy at scientific meetings and argument in 
journals. The reason for this, in the author's opinion, 
is clear. Of all the studies carried out on these 
patients, most have involved insufficient numbers to 
allow firm conclusions to be drawn. The use of endoscopy 
has revealed a new range of prognostic factors - stigmata 
of recent haemorrhage. Initial enthusiasm for early 
endoscopy seemed to wane with the observation that a 
policy of early endoscopy did not apparently reduce 
mortality. However, as pointed out in the introduction 
70% of patients admitted with UGIT haemorrhage will 
settle without further treatment. If a policy of
endoscopy for all is followed, it can only give
information of benefit in 30% of cases. Thus, if a 
treatment given on the basis of endoscopy were to be
successful in reducing, for example, the rebleeding rate
by a third and we want to be 90% certain of picking up a 
difference between the treatments at a significant level 
of 0.05, a study of over 800 patients would be required! 
(Fleiss 1981).
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This comment is not intended as a criticism of all 
research in this field although papers which describe 
controlled trials consisting of 10 or 12 patients in each 
group surely do little to inform the debate. It seems, 
however, that it is the descriptive, retrospective 
studies such as the classic work of Avery Jones (1956) 
which have advanced the understanding of the condition 
and thereby (possibly) improved prognosis.
An appreciation of the factors which worsen prognosis 
has allowed earlier surgery in a more appropriate group 
of patients. The identification of age, shock and 
anaemia as contributing to a poor prognosis and the 
resulting tendency of the clinical community to 
investigate and treat aggressively any patient recognised 
as falling into a high risk group has probably done more 
to improve outcome than the efforts of the pharmaceutical 
industry.
However, the clinical realities of the condition must 
be recognised. UGIT bleeding is caused by many different 
pathological processes in different parts of the upper GI 
tract, is affected by many different patient-associated 
factors and has many different possibilities for 
investigation and management. A compromise must be 
reached between the purist approach which demands 
hundreds if not thousands of patients in carefully 
matched study groups and a more intuitive, clinical 
approach which recognises the limitations of clinically 
based research. With these comments as background,
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several points need to be made about the studies in this 
thesis.
The introduction identified several studies 
advocating methods for treatment of patients with UGIT 
bleeding. None of these seem to be universally 
applicable and most seem to suffer from the defect 
mentioned above - that of the statistical type 2 error. 
H2 receptor antagonists may be useful but their 
intellectual appeal has not been confirmed in large 
studies. Most have included small numbers of patients 
and many are inconclusive. Indeed, the notion of 
reducing acid secretion in gastritis and gastric ulcer 
patients many of whom will already have reduced gastric 
pH is not particularly sensible. The concept that 
enhanced fibrinolysis in the UGIT is responsible for 
continued or recurrent bleeding is more appealing and 
seems to be more widely applicable. The theory was given 
more support by the paper by Henry and O'Connell (1989) 
which used metanalysis to deduce that an 
anti-fibrinolytic drug, tranexamic acid, improved outcome 
in UGIT bleeding patients. The experimental work 
reported in this thesis set out to establish how 
frequently the fibrinolytic system was upset in these 
patients. Could it be used to predict, for example, 
which patients would benefit from the use of tranexamic 
acid?
Accordingly a study of emergency admissions to the 
medical receiving unit of a general hospital was
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arranged. The constraints surrounding collection time for 
blood sampling (9 a.m.) prevented a strict sequential 
design for patient accrual and also prevented clear 
matching of patients into predetermined groups. Despite 
this, a group of 12'2 patients with an age and sex 
composition who were typical of the UGIT bleeding 
population as a whole was collected. The sample appeared 
to be a reasonable approximation of the population, and 
comparable to other reported series.
Clearly, there were several items of information 
where data could not be collected with precision. For 
example, patients are unlikely to have been completely 
honest about alcohol consumption. It seemed reasonable 
to try to differentiate between heavy drinkers and social 
drinkers and a deliberately low cut off point of 10 
units/week was chosen to make this distinction. No other 
means of assessing alcohol intake was available to the 
author, since blood alcohol estimation at the time of 
sampling only reflects the past few hours' consumption. 
In the event, it produced a plausible distribution of 
drinking habits with 44% admitting to social drinking and 
22% falling into the heavy drinking category. Drinking 
category did not contribute any predictive power to the 
multivariate analysis of prognostic factors.
Another compromise had to be made over laparoscopic 
accuracy. During the period of the study, the author had 
no GMC registration and was, therefore, legally 
prohibited from taking part in the clinical care of the
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patients. The diagnoses arrived at for the patients were, 
therefore, completely the responsibility of the several 
endoscopists. The author made no attempt to influence the 
endoscopist in his assessment of the bleeding source. 
"Gastritis" and "gastric erosions" are probably identical 
pathologies but it was felt that data collection would be 
simplified by taking the diagnosis as reported by the 
endoscopist rather than asking him to select from 
predefined categories. What this study has shown is that 
alterations in FDP level in acute UGIT bleeding occur 
irrespective of pathology, and if this study were to be 
repeated, it would be reasonable to narrow the diagnostic 
categories without loss of any information.
Some patients had received medical treatment directed 
at stopping bleeding by the time blood sampling for FDP 
measurement was undertaken. In most cases, this was an 
H2 receptor antagonist. As described, there was no 
association between receipt of these drugs and raised FDP 
level. This reflects a tendency amongst junior medical 
staff to prescribe these drugs in a "blanket" fashion to 
all patients admitted with a UGIT bleeding problem. No 
patients received tranexamic acid or prostaglandin 
agonists.
The biggest area of dissatisfaction in study design 
for the author lies in the fact that sampling had to take 
place at a standard time - 09.00 a.m. Although required 
by the diurnal variation of the FPLA level, it meant that 
many seriously ill patients could not be included in the
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study. Where clinical urgency required that endoscopy
and surgery was carried out without delay, the patient 
could not obviously wait for a standard sampling time. 
The endoscopy policy in this hospital, however, ensured 
that a number of severely ill patients did enter the 
study. Unlike some other hospitals there is no blanket 
policy to ensure that all UGIT bleeding patients are
endoscoped. Endoscopy is considered in the Royal
Infirmary to require consultant referral. This philosophy 
means that many patients wait until the end of the 
medical receiving round before an endoscopist is 
contacted with the request. As a result, it was the 
author's impression that earlier treatment might have
been obtained for some patients. These patients had 
received blood transfusions before sampling. The study 
reported in chapter VII supported the impression gained 
from the literature that transfused blood does not 
produce an increase in FDP or plasminogen activation. 
Although many patients went on to have more units of 
blood, no patient had had more than four units at the 
time of sampling at 09.00 a.m. The selection of the 
control patients for this study seems appropriate 
therefore.
If the selection of patients for study were 
controlled by expediency, the methods used to study them 
were not. The methods for measurement of FDP and FPLA 
are standard techniques which have been in use for two 
decades including the laboratory used by the author (Lowe
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and Prentice 1980). The normal ranges for a local 
population have been well established and a "normal" 
control population was not justified in view of the 
widely accepted nature of the tests as carried out in 
this laboratory. It should be re-emphasised that the 
patients described in chapter III were studied to confirm 
diurnal variation in the FPLA as carried out by the 
author not to validate the methods per se. It is not 
strictly correct to describe them as controls, therefore.
Their function was to demonstrate that the author could 
perform the laboratory analysis with sufficient accuracy 
and also to determine the best time for sampling in view 
of the diurnal variation in fibrinolytic activity. It 
was not to demonstrate a normal range which is already in 
the literature for this laboratory.
A final point relating to patient and method 
selection should be made with regard to the subjects 
described in chapter VIII. It was appreciated that a 
possible confounding factor in this study was the 
inclusion of so many patients with liver disease. Hepatic 
disorders are known to cause an elevation in serum FDP 
levels and it might be claimed that the elevation seen in 
patients with severe UGIT bleeding was due to severe 
liver disease (and oesophageal varices) rather than the 
haemorrhage. The multivariate analysis described in 
chapter V fails to support this point (oesophageal 
varices did not predict outcome) but it was felt 
necessary to establish for certain that bleeding caused
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an elevation in FDP in addition to that present due to 
liver disease. The opportunity to study this was 
afforded by the fact that this hospital has a large 
chronic sclerotherapy programme for oesophageal varices 
patients. Several of these patients were tested during 
admission for routine sclerotherapy in the knowledge that 
several of them would be admitted as an emergency during 
the study. This happened in eleven patients. The rise in 
serum FDP seen, even in patients with already elevated 
levels, supports the results of the earlier statistical 
analysis of chapter V, that raised FDP levels are related 
to bleeding rather than to pathology.
Having discussed the limitations on patient selection 
in this study, attention should now be paid to the 
results. It was clear that an elevation in serum FDP was 
associated with an increased likelihood of death or 
surgery. Issue could be taken with the decision to 
assess severity of illness according to the need for 
transfusion and the need for surgery or death. It is 
argued that to patients who, on clinical grounds do not 
need transfusion are likely not to have had a significant 
bleed. Patients who die of bleeding clearly have a 
serious lesion. In this study, seven of the eleven 
deaths occurred during uncontrolled haemorrhage. Of the 
other deaths, three were due to acute renal failure 
secondary to hypovolaemic shock. Two cardiac deaths were 
arguably contributed to by hypovolaemia and one death due 
to septicaemia occurred as a result of poor lower limb
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circulation and resulting gangrene. All the deaths 
could arguably therefore be due to the direct or indirect 
consequences of bleeding. Also the inclusion in this 
group of the surgical patients is justified on the 
grounds that in each case an experienced surgeon decided 
that continued or recurrent bleeding was unlikely to stop 
without surgical intervention. The group of middle 
severity, those requiring transfusion, is the one most 
subject to subjective influences. This group will include 
patients inappropriately transfused one or two units of 
blood right up to one patient given 29 units of blood but 
who was not referred for surgery. Clearly this is a very 
heterogeneous group reflecting the practices of many 
clinicians. Despite this, there was a significant 
increase in FDP level when group 1 was compared with the 
transfused group. The surgery/death group had a highly 
significant increase.
Plasminogen activation as determined by FPLA was 
inversely related to outcome, and an explanation for this 
observation (high PA1 levels) had been advanced in the 
relevant chapter. This remains to be tested in future 
studies. Regardless of the explanation for FPLA changes, 
it is clear that an elevated FDP level in plasma is a 
highly sensitive index of severity in UGIT bleeding, and 
in the 36 patients for whom serum was still available for 
testing. The sitaple Thrombo-Wellcotest identified 
correctly all five patients requiring surgery or who 
died. The results from this small study give the test a
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specificity of 94% and a sensitivity of 100%. These 
figures are impressive and when it is remembered that 
this test takes 30 seconds to perform, it suggests that 
the Thrombo-Wellcotest could be an integral part of the 
assessment of UGIT bleeding patients. This requires 
validation in a future study.
It is this aspect of the study which is put forward 
as being the original contribution of this thesis. The 
various criticisms concerning patient selection in a 
sense become irrelevant beside this fact. It does not 
really matter what the patients died of, the test seems 
able to predict the most seriously ill. It does not 
really matter whether the patients came to surgery for 
continuing primary haemorrhage or for rebleeding, the 
test was able to determine on the morning following 
admission whether or not the patient fell into a high 
risk group. The multivariate analysis confirmed that the 
predictive power of a raised FDP level was greater than 
any of the conventional indicators.
Some information has been gained as to the cause of 
the elevated indices of fibrinolysis. The raised FDP 
level might occur as a result of absorption of soluble 
clot fragments into the blood stream from the UGIT, and 
does not appear to result from blood transfusion.
This study suggests other experimental work. If the
origin of the FDP is enhanced fibrinolysis in the
stomach, rather than systemically, this possibility could 
be examined by sampling from gastric vein and a
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peripheral artery to obtain an A-V difference for FDP 
across the stomach. This was considered for this study, 
but ethical committee permission was not envisaged on the 
grounds that these samples added a small but significant 
hazard to the surgical procedure. With the benefit of 
the results of this study now being available, a stronger 
case for investigation of these levels could perhaps be 
made.
The important study which now needs to be done is to 
assess the effects of tranexamic acid in these patients 
using the Thrombo-Wellcotest to select a high risk group. 
If this showed a clear cut benefit, particularly in the 
varices patients, this would benefit management of acute 
UGIT bleeding. As it is, the case for enhanced local
fibrinolysis playing an important role in breaking down
clot formation in bleeding vessels in the UGIT seems
stronger as a result of the findings reported in the
present thesis.
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Appendix 1
Case Record for patients with upper GI bleeding
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Study .Vo.Xarr.e 
Address  
Telephone Xo.
G.P.
H o s p i t a l  Xo.
Date o f  Birth
Sex , 1 .  Male . 2 .  Female
Ward
C onsultant
D a t e ' o f  Onset o f  Bleedir.g 
Date o f  Admission 
Date seen
Haemodynamic s t a t e  (worst  data)
Pulse  B/min
B.P. S y s t o l i c / D i a s t o l i c
U n i t s  o f  blood transfused  
U n it s  of  p la s m a /c o l lo id  
U n i t s  of  c r y s t a l l o i d
Clinical features
Haematemcsis
Melaena
Drugs
Smoking 
Liver d i s e a s e
Previous  p e p t i c  
u lc e r  d i s e a s e
Prev ious  C-I b leed
1. Yes 2.  Xo | |
1. Yes 2 .  Xo Q j
1. XSAID .• 4 .  More than 1
2.  S t e r o i d s  5 .  Xone
3 .  A n t ico a g u la n ts  • 6. Othe;
Cigs /day
1. Yes 2.  Xo
1. Yes 2 .  Xo
1. Yes 2.  Xo
□
□
□
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A lco h o l . 1. None
2.  P r e v io u s  d r in k er
3 .  S o c i a l  d r in k er
4.  Heavy
5. Not known
□
Height  : cm. 
Weight kg .  
fo I d e a l  body wt .
R o u t in e  l a b o r a t o r y  da ta  
Hb.
Serum B i l i r u b i n  
Serum C r e a t i n i n e
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Name
Study No 
Sheet  2 .
Endoscopy f i n d i n g s
Oesophagus 1. Normal
2. O e s o p h a g i t i s
3 .  H ia tu s  h ern ia  
4.. M -  T,7
"5. ' Viti. xces
6.  Carc-inoma
7 .  Other
9. Not seen
Stomach 1.  Normal
2 .  G a s t r i t i s .
3 .  Carcinoma
4 .  G a s t r i c  u l c e r
5 .  G a s t r i c  e r o s i o n s
6 .  Other
9.  Not seen
□
Duodenum 1. Normal'
2 .  D u o d en i t i s
3 .  Duodenal u l c e r
4 .  Other
9 .  Not seen
Stoma 1.  U lc e r  .
2 .  Normal 
9. Not seen
□
Source  o f  
b l e e d . 1.  Oesophagus 
*2.. Stomach
3 .  Duodenum
4.  Stoma
□
S t ig m a ta  1.  V i s i b l e  v e s s e l
2 .  A c t iv e  b l e e d in g
3 .  Slough .
4 .  Fresh c l o t
5 .  None
□
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Laboratory i n v e s t i g a t i o n s
F ib r in  p l a t e  
• F .D .P .
C oa g u la t io n  s c r e e n  1. Normal
. 2.  Abnormal 
.3. Not done
□
Drug treatm ent
1. A ntac id s
2 .  C i m e t i d i n e / R a n i t i d i n e
3 .  P r o s t a g l a n d i n s  
4‘. Somatos-tatin
5 .  Tranexamic a c id
6. More than 1
7 .  Other  
9.  None
□
Further bleeding 1. Yes
Hb. Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7
T o t a l  u n i t s  b lood t r a n s f u s e d
2. No □
□
Surgery 1. Yes 2.  No □
Ooerat ion  c a r r i e d  out:
□Undersewing o f  v e s s e l 1. Yes 2.  No
Other procedures 1. Vagotomy & drainage
2. P a r t i a l  gastrectomy
1 1 1
3 .  T ota l  gastrectom y
4 . ’ I n j e c t i o n  o f  v a r i c e s
5 .  T ra n se c t io n  o f  oesophagus
6. Laparotomy a lone
7. Other
8. More thap,ope
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OUTCOME
Hospital survivor 1. Yes .2. No
Date of discharge
Alive at 1 month 1. Yes 2. No
If Yes ? Further bleed 1. Yes 2. 
Date of death
• E m
□
No □
Post Mortem 1. Yes 2. No □
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Appendix 2
Case Record for patients with oesophageal varices
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No:
Name:
Hospital No.:
Date of Birth:
Sex:
The sample is taken at:
Date of the first injection:
Dates of the subsequent injections:
Portal hypertension is caused by:
Pugh's modification of Child's classification: 
Encephalopathy:
Ascites:
Bilirubin - - -  - -  - -  - -  - -  - - - - -  - mmol/1
Albumin - - - - - - - - - - - - - - - -  gram/1
Prothrombin - - - - - - - - - - - - - - -  second
Grade:
A ---------
B ----------
C  -------
F.D.P.: -------
F.P.L.A.: - - —
Hb
AST
ALT
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Appendix 3
Forms used to record F.D.P. and F.P.L.A. 
values of patients
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Name 
Address:
Hospital No.
Date of Birth
Sex
Ward
Consultant
Date of Admission
Date of Sample I
Date of Blood Transfusion
Date of Sample II
Diagnosis
F.D.P. before Transfusion 
F.D.P. after Transfusion 
F.P.L.A. before Transfusion 
F.P.L.A. after Transfusion
- 256 -
APPENDIX 4
Abbreviated case histories of patients requiring 
surgery or who died
Patient No. 80
A 52 year old woman was admitted to the surgical ward 
with bleeding oesophageal varices. She was treated by 
sclerotherapy and tamponade with blood transfusion. Her 
condition stabilised but after 3 days, torrential 
rebleeding occurred and cardiovascular collapse followed. 
Despite considerable efforts at resuscitation, she died. 
Cause of death was haemorrhage.
Patient No. 112
A 35 year old man was admitted to the surgical unit 
because of oesophageal variceal bleeding. He was treated 
conservatively but 24 hours later he had a further 
haematemesis and a sengstaken tube was placed after 
sclerotherapy. After 3 days, his condition remained poor 
and he was oliguric. On the 4th day after admission, 
rigid oesophagoscopy was carried out with injection of 18 
mis of ethanolamine into his oesophageal varices. His 
cardiovascular condition immediately following this 
procedure was good. He became more alert and orientated 
but his urine volume remained poor and ultimately he died 
from acute renal failure.
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Patient No. 113
A 58 year old man was admitted to the surgical ward 
because of haematemesis. He was known to have alcoholic 
liver cirrhosis. In the previous three years he had been 
admitted frequently to hospital because of variceal 
bleeding. He had had repeated courses of elective 
sclerotherapy for his varices. On admission, he was 
confused and hypotensive with blood pressure 70/30 and 
p.r. 120/minute. He was not in hepatic coma. 
Resuscitation was started and he underwent balloon 
tamponade with urgent sclerotherapy. He rebled 24 hours 
after release of the tamponade and he underwent further 
rigid oesophagoscopy and sclerotherapy but unfortunately 
died after 24 hours. The cause of death was 
haemorrhage.
Patient No. 118
A 33 year old man was admitted to the surgical ward 
because of massive haematemesis. He was known to have 
alcoholic liver cirrhosis. He underwent resuscitation 
and his varices were treated by balloon tamponade and 
sclerotherapy. Cardiovascular collapse caused death 
despite apparent control of his varices. Post mortem 
showed that the cause of his death was recurrent massive 
bleeding.
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Patient No. 122
A 35 year old man was admitted to the surgical ward 
with severe haematemesis. On admission he gave a history 
of considerable alcohol abuse for some years. At the time 
of his admission he was transfused 8 units of blood and a 
sengstaken tube was immediately inserted. This failed to 
control his bleeding after one day and he also became 
very unco-operative and pulled his tube out. Endoscopy 
was undertaken immediately thereafter. This showed 
oesophageal varices with one varix spurting blood. The 
patient would not co-operate with the passage of another 
sengstaken tube and was therefore started on an infusion 
of intravenous somatostatin. He had been transfused 30 
units of blood over two days. Endoscopy was therefore 
undertaken under general anaesthetic. At this time only 
old blood could be found in the oesophagus, stomach and
duodenum although there was occasional very slight
bleeding from mucosal surfaces. Overnight his general
condition deteriorated further and he died. The
probable cause of death was haemorrhage.
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Patient No. 3
A 70 year old lady was admitted as an emergency to
the medical receiving unit with a haematemesis. The day
after admission she had a further significant bleed and 
she was transferred for emergency gastric surgery. At
operation, the findings were of a benign ulcer on the 
lesser curve of her stomach. This was dealt with by 
oversewing and a truncal vagatomy and pyloroplasty was 
also carried out. She was discharged home on her 12th 
post-operative day.
Patient No. 15
A 65 year old man was admitted to the surgical ward 
with evidence of upper GI bleeding. Endoscopy revealed a 
pre-pyloric gastric ulcer and control of the bleeding was 
obtained by laser therapy. Thereafter his condition 
unfortunately deteriorated and he complained of abdominal 
pain and hypotension. He was transferred to the renal
unit because of deterioration in his renal function but 
unfortunately, despite haemodialysis, he died. He is 
known to have had hypertension since 1967 and had a 
myocardial infarction in 1981. The immediate cause of 
death was congestive cardiac failure. Perforation of his 
ulcer was not thought likely on clinical and radiological 
grounds.
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Patient No. 40
A 73 year old woman was admitted to the surgical ward 
because of haematemesis and melaena. She was treated by 
blood transfusion and a gastric ulcer was confirmed by 
endoscopy. Two days later she had a further significant 
bleed and she underwent emergency surgery. At
laparotomy a gastric ulcer was found. This was treated 
with oversewing and trancul vagotomy and pyloroplasty was 
carried out. She was able to be discharged on the 10th 
post-operative day.
Patient No. 91
An 85 year old woman was transferred to the care of 
the surgeons as an emergency with a massive haematemesis 
following internal fixation of her right hip. She was
severely hypotensive on arrival in theatre. The stomach
was opened and the source of the bleeding was seen to be 
a large benign ulcer on the lesser curve of the stomach
with a large vessel in its base which was actively
bleeding. The vessel was under-run and the ulcer 
oversewn and vagotomy and pyloroplasty was performed. 10 
days post-operatively she was able to go home.
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Patient No. 25
A 35 year old was admitted to the surgical ward with 
a haematemesis. She was hypotensive (B.P. 60/0) on
admission. Subsequently her sister admitted that she had 
taken an unknown quantity of NSAID tablets. Replacement 
of blood loss was started via a central venous line and 
she had an upper GIT endoscopy on the same day. Erosive 
gastritis was confirmed at endoscopy. Massive bleeding 
was observed. The patient unfortunately died two days 
later because of acute renal failure secondary to 
prolonged hypotensive shock.
Patient No. 12
A 53 year old man was admitted to the surgical ward 
because of haematemesis and melaena. He was known to
have gastric cancer for the previous 2 years. On
admission he was pale and hypotensive (B.P. 60/40). He 
received 8 units of blood and his condition stabilized 
but he had continuous vomiting due to outlet obstruction. 
Two days later he underwent surgery. A gastro 
jujenostomy was carried out. Five days later he
developed hypotension and chest pain and died after a 
period of deterioration. Primary cause of death was 
recorded as acute renal failure.
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Patient No. 27
A 30 year old gentleman was admitted to the surgical 
ward with a 2 day history of haematemesis and melaena. In 
the past six months he had complained of dyspepsia and 
occasional vomiting after meals. On admission he was 
confused and shocked. He was stabilized by vigorous 
resuscitative measures. Subsequent gastroscopy revealed 
a cauliflower mass in the lower part of the greater 
curvature of the stomach extending to the pylorus and on 
biopsy later proved to be an adenocarcinoma. One week 
later he underwent gastro jujenostomy and was discharged 
7 days later.
Patient No. 28
The patient was admitted to the ward as an emergency 
a few days after returning home following his coronary 
artery bypass graft. He had several units of blood in 
the Lewis Hospital and seemed stable when he came in but 
within an hour of admission his blood pressure dropped 
and he became severely unwell.
He was taken immediately to theatre where vagotomy 
and pyloroplasty and oversewing of an extremely large 
bleeding vessel in duodenal ulcer was undertaken. 
Following this he made an excellent recovery and by two 
weeks was fit enough to return home.
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Patient No. 32
A 63 year old man presented with a 2 day history of 
melaena and a 5 day history of gastric discomfort. In 
the past, he had undergone a truncal vagotomy and 
pyloroplasty for duodenal ulcer disease. On examination 
he was pale but haemodynamically stable. Three days later 
he was noted to be dizzy when standing and his 
haemoglobulin on that day was 4.5 gm. per 100 ml. 
Gastroscopy examination showed visible bleeding from a 
duodenal ulcer. He was taken immediately to theatre 
where truncal vagotomy and antrectomy was carried out. He 
was well at the time of discharge on the 10th 
post-operative day.
Patient No. 41
An 82 year old woman was admitted to the medical ward 
because of haematemesis. She has a history of previous 
myocardial infarction and duodenal ulcer. One day before 
admission she had had upper abdominal pain with coffee 
ground vomiting but her condition was stable. However, 
during her stay in hospital, she deteriorated with signs 
of shock. She died in the next 24 hours of her admission 
due to a combination of hypovolaemia and pump failure 
from myocardial infarction.
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Patient No. 46
A 40 year old woman was admitted to the receiving 
medical ward with a two day history of haematemesis. On 
the day of admission she had a further significant 
bleeding for which she was transfused and transferred to 
the surgical ward. At laparotomy a bleeding duodenal 
ulcer was discovered which was treated by under-running, 
truncal vagotomy and pyloroplasty. She was discharged 
well on 10th post-operative day.
Patient No. 72
A 64 year old man was admitted as an emergency to the 
medical receiving unit with haematemesis. He had a 
further significant bleeding shortly after admission. He 
was transfused and transferred for emergency surgery. At 
laparotomy a duodenal ulcer was discovered which was 
freely bleeding. The ulcer was dealt with by oversewing, 
truncal vagotomy and pyloroplasty. He made an excellent 
recovery from surgery and was able to go home on the 12th 
post-operative day.
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Patient No. 82
An 80 year old woman was admitted to the surgical 
ward because of severe haematemesis. On admission she 
was pale and hypotensive (B.P. 40) and radial pulses were 
not palpable. A central venous line was established and 
vigorous resuscitation measures were started. She was 
taken to the operating theatre where she underwent 
gastroscopy and an active bleeding duodenal ulcer was 
detected. Laser photocoagulation was attempted but the 
patient succumbed due to blood loss.
Patient No. 90
An 84 year old man was admitted to the emergency ward 
with haematemesis. In the past he had a history of 
duodenal ulcer which had been confirmed by endoscopy. He 
continued to have haematemesis and melaena in the next 24 
hours for which he received blood transfusion. Surgical 
intervention was undertaken in view of the continuous 
bleeding and his age. His duodenal ulcer was treated 
with oversewing sutures, truncal vagotomy and 
pyloroplasty. He was discharged well on the 12th 
post-operative day.
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Patient No. 102
A 59 year old man was admitted as an emergency with 
haematemesis and melaena. Although this was initially 
of a very minor degree, over the next few hours he had a 
substantial haematemesis and became shocked. He was 
therefore taken urgently to theatre for oversewing of a 
bleeding duodenal ulcer. Post-operatively his legs were 
noted to have compromised circulation and this was 
thought to be related to a period of shock during his 
bleeding. A vascular surgeon felt that embolectomy would 
not be helpful. He spent some days in I.C.U. following 
his operation but he did not make a good recovery. The 
circulation in his lower limbs never became 
re-established. His condition deteriorated rapidly and 
finally he died five days post-operatively at which time 
he was severely hypotensive. Probable cause of death was 
sepsis related to his ischemic limbs.
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